**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 75860

**Manuscript Type:** REVIEW

**Insulin-resistance in paediatric age: Its magnitude and implications**

Al-Beltagi M *et al*. Insulin-resistance in paediatric age

Mohammed Al-Beltagi, Adel Salah Bediwy, Nermin Kamal Saeed

**Mohammed Al-Beltagi,** Department of Pediatrics, Faculty of Medicine, Tanta University, Tanta 31511, Egypt

**Mohammed Al-Beltagi,** Department of Pediatrics, University Medical Center, Arabian Gulf University, Dr. Sulaiman Al Habib Medical Group, Manama 26671, Bahrain

**Adel Salah Bediwy,** Department of Chest Disease, Faculty of Medicine, Tanta University, Tanta 31527, Egypt

**Adel Salah Bediwy,** Department of Pulmonology, University Medical Center, Arabian Gulf University, Dr. Sulaiman Al Habib Medical Group, Manama 26671, Bahrain

**Nermin Kamal Saeed,** Medical Microbiology Section, Department of Pathology, Salmaniya Medical Complex, Ministry of Health, Manama 12, Bahrain

**Nermin Kamal Saeed,** Microbiology Section, Department of Pathology, Irish Royal College of Surgeon, Busaiteen 15503, Bahrain

**Author contributions:** Al-Biltagi M, Bediwy AS, and Saeed NK collected the data and wrote and revised the manuscript.

**Corresponding author: Mohammed Al-Beltagi, MBChB, MD, MSc, PhD, Chairman, Professor,** Department of Pediatrics, Faculty of Medicine, Tanta University, Al Bahra Street, Tanta 31511, Egypt. mbelrem@hotmail.com

**Received:** February 18, 2022

**Revised:** March 12, 2022

**Accepted:** March 27, 2022

**Published online:** April 15, 2022

**Abstract**

Insulin resistance (IR) is insulin failure in normal plasma levels to adequately stimulate glucose uptake by the peripheral tissues. IR is becoming more common in children and adolescents than before. There is a strong association between obesity in children and adolescents, IR, and the metabolic syndrome components. IR shows marked variation among different races, crucial to understanding the possible cardiovascular risk, specifically in high-risk races or ethnic groups. Genetic causes of IR include insulin receptor mutations, mutations that stimulate autoantibody production against insulin receptors, or mutations that induce the formation of abnormal glucose transporter 4 molecules or plasma cell membrane glycoprotein-1 molecules; all induce abnormal energy pathways and end with the development of IR. The parallel increase of IR syndrome with the dramatic increase in the rate of obesity among children in the last few decades indicates the importance of environmental factors in increasing the rate of IR. Most patients with IR do not develop diabetes mellitus (DM) type-II. However, IR is a crucial risk factor to develop DM type-II in children. Diagnostic standards for IR in children are not yet established due to various causes. Direct measures of insulin sensitivity include the hyperinsulinemia euglycemic glucose clamp and the insulin-suppression test. Minimal model analysis of frequently sampled intravenous glucose tolerance test and oral glucose tolerance test provide an indirect estimate of metabolic insulin sensitivity/resistance. The main aim of the treatment of IR in children is to prevent the progression of compensated IR to decompensated IR, enhance insulin sensitivity, and treat possible complications. There are three main lines for treatment: Lifestyle and behavior modification, pharmacotherapy, and surgery. This review will discuss the magnitude, implications, diagnosis, and treatment of IR in children.

**Key Words:** Insulin resistance; Children; Diabetes mellitus; Obesity; Genetic; Acquired

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Al-Beltagi M, Bediwy AS, Saeed NK. Insulin-resistance in paediatric age: Its magnitude and implications. World J Diabetes 2022; 13(4): 282-307

**URL**: https://www.wjgnet.com/1948-9358/full/v13/i4/282.htm

**DOI**: https://dx.doi.org/10.4239/wjd.v13.i4.282

**Core Tip:** Insulin resistance (IR) increases in children due to lifestyle changes and the pandemic of obesity. There is a strong association between obesity in children and adolescents and IR. There is a broad range of genetic and acquired causes of IR with a wide variability of its prevalence from one country to another. Many available tests can directly or indirectly estimate IR. To prevent future IR, we should target all the factors that could help the development of IR, especially obesity.

**INTRODUCTION**

Initial data suggest that insulin resistance (IR) is becoming more common in children and adolescents than before. IR is insulin failure in the normal plasma levels to adequately stimulate glucose uptake by the peripheral tissues such as adipose tissues and skeletal muscle, inhibit the hepatic gluconeogenesis and release of glucose into circulation, and/or suppress the output of very-low-density lipoprotein[1]. IR is a spectrum disorder that ranges from very mild to very high resistance and is commonly associated with obesity. Consequently, chronic hyperinsulinemia occurs as a compensatory mechanism to IR[2]. There is a strong association between obesity in children and adolescents, IR, and the metabolic syndrome (MS) components, including the high risk of cardiovascular complications[3]. IR syndrome (IRS) is characterized by the presence of hyperinsulinemia and one or more of the following: impaired glucose tolerance, central obesity, hypertension, hirsutism, hypertriglyceridemia, hypercholesterolemia, reduced high-density lipoprotein, high low-density lipoprotein, hyperuricemia, coagulation abnormalities favoring thrombosis, polycystic ovary syndrome and/or menstrual disturbances[4]. Table 1 shows various forms of IR.

**EPIDEMIOLOGY OF IR IN CHILDREN**

IR is rising due to increasing obesity among children and adolescents, changing the lifestyle with lack of physical activities, high-calories intake (western diet style), overdependence on the technology with more sedentary life due to TV watching, and social media addiction. Although IR usually occurs in obese people, not all obese people have IR. It may also occur in normal physiological status during puberty or pregnancy[5]. IR may appear as early as two years of age in children with certain genetic predisposition and environmental influences (*e.g.*, decreased activity) with a peak at puberty due to increased growth hormone secretion[6]. IR prevalence in children varies from one country to another depending on many factors, including genetic, racial, and environmental factors, and due to the heterogeneity of the methods of data collection and the cut-off values used to define IR. In a systematic review study by van der Aa *et al*[7], the overall prevalence rates of IR ranged between 3.1% and 44% of children and adolescents, being more prevalent in girls than boys due to their earlier pubertal changes. They also found that IR reached 68.4% in obese boys. Jurkovičová *et al*[8] show an IR prevalence rate of 18.6% in Slovakian adolescents with significant association with insufficient physical activity, low level of physical fitness, a small number of daily meals and breakfast skipping, more sweetened beverages consumption, and low educational level of fathers.

IR is higher in urban than rural children and among Hispanics, American Indians, African Americans, East Asians, and South Asians than white European adolescents. However, it is increasingly observed across all racial boundaries, particularly with the increasing obesity rate. In a cross-sectional study of urban Indian schoolchildren, Das *et al*[9] found that the overweight or obesity rates were 28.2%; about 21.8% of them had IR. Adolescence increases the risk of IR. Arslanian *et al*[10] showed that the IR rate was higher in obese adolescents than in obese adults, despite similar degrees of adiposity and glycaemic status. This observation could explain the relatively poor response of these obese children to metformin and the rapid decline of β-cell function observed in adolescents than in adults with diabetes mellitus (DM) type-II. IR shows marked variation among different races. Raygor *et al*[11] show that the overall IR was less in non-Hispanic Whites and African Americans than East Asians and South Asians. Ehtisham *et al*[12] also showed that South Asian adolescents have significantly more IR and body fat than white European adolescents, which may increase their risk of developing DM type-II. They attributed these racial differences to the ethnic differences in the composition of children's body fat. These racial differences are crucial to understanding the possible cardiovascular risk, specifically in high-risk races or ethnic groups.

**PATHOGENESIS OF IR**

IR is multifactorial.

**Physiologic Effects of Insulin**

Insulin is a hormone produced from proinsulin in the beta cells of the pancreas when stimulated by elevated blood glucose. Proinsulin is broken apart, leaving insulin and C-peptide. Both are secreted and enter the bloodstream in equimolar amounts. Because insulin and C-peptide are equally secreted, both can be used to quantify endogenous insulin production. Average fasting serum C-peptide or insulin values are around 0-30 µIU/mL. The average daily insulin requirement is 0.5-0.7 units/kg of body weight[3]. Insulin stimulates the amino acids' entry into body cells. It enhances protein synthesis and fat storage and prevents fat mobilization for energy. It also promotes glucose entry into cells as an energy source. It has euglycemic effects by promoting glucose storage as glycogen in muscle and liver cells and inhibiting glucose production from liver or muscle glycogen from non-carbohydrates[13]. Insulin action starts by binding to a surface glycoprotein receptor expressed on the target cell's surface. This insulin receptor is composed of an alpha-subunit and a beta-subunit. Alpha unit binds the insulin, while beta-subunit is a tyrosine-specific protein kinase stimulated upon binding insulin to alpha subunit. This kinase activation generates a specific signal that ultimately results in insulin's effects on glucose, protein, and lipid metabolism. Insulin also mediates its growth-promoting effects by activating receptors linked to insulin-like growth factors[14]*.* IR does not necessarily involve all the insulin-dependent pathways (partial IR). In partial IR, some manifestations such as hyperinsulinemia, hyperglycemia, hyperandrogenism, ovulatory dysfunction, soft tissue overgrowth, and acanthosis nigricans may present while the patients may have average lipid profiles[15,16].

**Genetic Basis for IR**

As many molecular pathways are concerned with energy homeostasis, protein and lipid metabolism, and insulin receptor functioning mechanism, many genetic mutations can end with IR development (Table 2). Insulin receptor mutations, mutations that stimulate autoantibody production against insulin receptors, or mutations that induce the formation of abnormal glucose transporter 4 (GLUT4) molecules or plasma cell membrane glycoprotein-1 molecules; all cause abnormal energy pathways and end with the development of IR. Mutations in the lipid pathway such as mutations in the adipocyte-derived hormones or their receptors (leptin, adiponectin, resistin), mutations in the peroxisomal proliferator-activated receptors (α, γ, δ), the mutation in the lipoprotein lipase gene, and other genes concerned with adipose tissue formation; all these mutations have a significant role in the development of IR. At the same time, mutations in proteases and serpin protease inhibitors cause IR and DM type II. The *CAPN10* gene is also engaged in GLUT4 vesicle translocation during the insulin-stimulated glucose uptake by adipocytes; it is also associated with IR and type 2 diabetes[17]. These mutations could occur in heterozygous or homozygous forms. The occurrence of several heterozygous mutations in the same person (a compound heterozygote) even when recessive; could have additive effects and produce significant consequences[18,19]. Insulin receptor pathway defects may occur due to mutations of the insulin receptor gene, causing a broad spectrum of inherited IRS, including type A syndrome of extreme IR, leprechaunism, Rabson-Mendenhall syndrome, and polymorphism in plasma cell membrane glycoprotein-1[20]. Insulin-like growth factor 1 (somatomedin C or IGF-1) is a hormone produced mainly by the liver, like insulin in the molecular structure, and plays a crucial role in childhood growth.

Growth hormone (GH) stimulates IGF-1 production[21]. Low IGF-1 levels are associated with many conventional cardiovascular risk factors related to increase IR. Kuang *et al*[22] found that obese prepubertal boys had lower IGF-1 standard deviation scores than boys without obesity and that whole-body insulin sensitivity index was positively correlated with IGF-1. Peroxisome proliferator-activated receptors (PPARs) are a group of ligand-activated transcription factors of the nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. Activation of PPAR-α reduces triglyceride levels and is involved in regulating energy homeostasis. Activation of PPAR-γ causes insulin sensitization and enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism. Thus, the PPAR family of nuclear receptors plays a significant regulatory role in energy homeostasis and metabolic function. Mutations of this family induce IR[23,24].

**Acquired Causes of IR**

The parallel increase of IRS with the dramatic increase in the rate of obesity among children in the last few decades indicates the importance of environmental factors in increasing the rate of IR. Acquired causes of IR include lack of physical activity, exogenous obesity due to excess food intake, drugs, glucose toxicity due to hyperglycemia, increased free fatty acids, and the aging process. Puberty itself is occasionally associated with IR[25]. The development of polyclonal autoantibodies against insulin receptors preventing insulin from its action is a rare condition known as type B IRS, which should be distinguished from type A IRS[26]. IR may occur due to excess insulin antagonists in excessive steroid production such as Cushing syndrome, acromegaly, and stressful situations such as severe infection, trauma, surgery, uremia, diabetes ketoacidosis, and liver cirrhosis. Certain medications may also increase the risk of IR, such as glucocorticoid therapy, niacin, cyclosporine, and protease inhibitors[27]. Treatment with growth hormone can elicit transient IR. High sodium consumption causes hypertension, enhanced glucocorticoid production, and IR[28]. Protease inhibitor used as a part of anti-human immunodeficiency virus therapy is associated with lipodystrophy and IR. Nucleoside analogs, *e.g.*, acyclovir and abacavir, may also induce IR[29]. Insulin therapy can induce anti-insulin antibody formation, which is usually present in low titers in most patients. However, in rare cases, these antibodies can cause significant IR (pre-receptor or insulin-autoimmune syndrome) with enhanced insulin destruction at the subcutaneous injection site[30].

**Risk Factors for IR**

Alongside the genetic factors that play a fundamental role in the development of IR, other factors could have significant contributing effects. Babies born for mothers with DM, whether pregestational or gestational, are at risk for future development of impaired insulin sensitivity and obesity even when they have an average birth weight[31]. The presence of hyperglycemia in pregnant mothers even without other signs of gestational diabetes is a mere risk factor for future IR and obesity in the offspring[32]. Children born to mothers with DM type I are more prone to have DM type II than children born with paternal DM type I[33]. Although many babies of mothers with gestational diabetes have excess body fat, the association of excess adiposity observed in these babies with the future development of IR is controversial[31]. The large birth size shows no association with later development of IR and impaired β-cell function in infancy. However, Huang *et al*[34] showed that the growth pattern during infancy could be related to the development of IR as decelerated infancy growth may be unfavorable to beta-cell function.

IR risk is high in newborns with small gestational age (SGA). However, studies showed that IR was not related to the birth weight but was related to the rate of weight gain during catch-up growth, especially in girls[34]. SGA may also result from IR's genetic causes as insulin is a potent antenatal growth hormone. Children born as SGA tend to have more intra-abdominal visceral fat than those with appropriate weight for age, even before the development of obesity. They are at more risk of having IRS in adolescence[35,36].

Consequently, SGA could be one of the manifestations of inherited IR with diminished fetal growth[37]. So, the relation between the birth weight and the risk of IR may follow a U-shaped relation[38]. Dabelea *et al*[39] showed that Pimas with low birthweight are thinner by 5-29 years. However, they are more insulin resistant and more liable to have DM type II than Pimas with average birth weight.

On the other hand, Pimas with high birth weight are more liable to be obese but less liable for IR regarding their body size[39]. Murtaugh *et al*[40] also observed similar findings. They showed a U-shaped relation between birth weight, body mass index (BMI), and fat mass in adolescents. So, children who rapidly gain weight are more liable to have IR, including preterm babies, during their rapid catch-up growth[41]. Ethnicity could pose a significant risk for IR as ethnicity and race affect glucose metabolism and insulin regulation. However, there are no international guidelines to address these racial/ethnic effects and recommend specific clinical advice[42]. Puberty is a physiological risk factor for IR due to various metabolic and hormonal changes. Insulin sensitivity drops by 25%-50% during puberty, reaching nadir by mid-puberty, then normalizes by the end of puberty. However, occasionally, puberty-induced IR does not resolve by the end of puberty, especially in adolescents who are obese, increasing the cardiometabolic risk of IR[43].

Deficiency of vitamin D is associated with many chronic conditions and diseases, including obesity, and increased metabolic dysregulation severity, such as IR and hyperlipidemia. Vitamin D performs a crucial role in the adipogenesis process and inflammatory condition in adipocytes and adipose tissue. Additionally, vitamin D can regulate adipocyte apoptosis and the gene expression responsible for the adipogenesis process, oxidative stress, inflammation, and metabolism in mature adipocytes. An adequate 1,25-dihydroxyvitamin D3 level is essential for normal insulin secretion[44,45]. Pires *et al*[46] showed that vitamin D deficiency in children with overweight or obesity increases the risk of IR during puberty.

Obesity is the most predominant pathophysiological risk factor of IR. IR positively correlated with the body mass index and proportion of body fat. Children with overweight or obesity have lower insulin sensitivity than children with average body weight[47]. The body fat distribution is also a significant risk factor that can predict IR. Although subcutaneous and visceral adipose tissues are related to IR, visceral adipose tissues more strongly correlate with IR than subcutaneous adipose[48]. Both subcutaneous and visceral adipose tissues secrete free fatty acids into the blood, correlated with the fatty mass. The higher the plasma-free fatty acid levels are, the more will be the IR. Visceral adipose tissues have more glucocorticoid receptors and elevated local glucocorticoids concentrations, which contribute to the development of metabolic screen[49]. In addition, visceral adipose tissues correlate with adiponectin levels, the degree of endothelial dysfunction and blood levels of C-reactive protein (CRP), interleukin-6 (IL-6), and degree of systemic inflammation. In addition, ectopic non-visceral or subcutaneous fat deposition, such as intramyocellular fat in adolescents with obesity, is also associated with reduced peripheral insulin sensitivity[50].

Sex affects the impact of fat distribution on the development of fat resistance. In males, abdominal subcutaneous and visceral adipose tissues are associated with IR, while in females, visceral adipose tissues are associated with IR and insulin secretion. The lifestyles such as physical activity and nutritional behavior; have a poorly defined relationship with insulin sensitivity in the pediatric age[51]. However, increased caloric intake is a leading cause of obesity, IR, and hyperinsulinemia. A saturated fatty diet and sweetened beverages could be associated with altered insulin sensitivity and secretion. However, Weigensberg *et al*[52] showed that these changes were more observed in black but not white children, related to underlying ethnic differences. The consequence of lack of physical activity on IR, independent of weight changes and adiposity, remains debated. Marson *et al*[53] showed that exercise training, especially aerobic training, reduces the fasting insulin levels and IR indices in children and adolescents with obesity or overweight and may prevent the development of the MS and DM type II.

Some diseases make the child more susceptible to more increased risk of IR. Boys with Klinefelter syndrome may have truncal obesity, IR, and other features of MS as early as 4–12 years due to reduced physical activity[54]. In children with asthma and obesity or overweight, there is an increased risk of IR, which, together with obesity and MS, worsens lung function. These factors interact together, making asthma control more difficult[55]. Obstructive sleep apnea (OSA) is a common comorbidity in children with obesity. OSA induces sympathetic activation and enhances the development of IR[56]. In addition, the use of certain medications could increase the risk of IR. Systemic steroids used in managing various disorders commonly have significant adverse effects on body weight and insulin sensitivity[57]. Various psychotropic medications induce significant weight gain and IR, commonly observed soon after therapy[58].

**CONSEQUENCES OF IR IN PEDIATRIC AGE**

Most patients with IR do not develop DM type-II. However, IR is a crucial risk factor to develop DM Type-II in children. Two critical factors are needed to develop DM type-I: impaired β-cell function and IR[59]. The genetic basis of the patients determines the response of pancreatic β-cells to hyperinsulinism and IR. Children and adolescents with obesity and IR are more liable to impaired glucose tolerance than those with obesity but without IR[60]. However, Cali *et al*[61] showed that children with obesity who developed impaired glucose tolerance had a primary defect in β-cell function and insulin-resistant presence just served as an aggravating factor. The risk to develop DM type II can be predicted using the disposition index as IR alone is not enough to expect the risk of DM type II. This index measures the ability of the beta cell to secrete insulin in response to a glucose load.

Consequently, children with IR and hyperinsulinemia are at increasing cardiometabolic risk of developing MS in the different ethnic groups[62]. IR is associated with high levels of circulating endothelial dysfunction biomarkers (E-selectin and intercellular adhesion molecule) and decreased antiatherogenic adipocytokine adiponectin levels[63]. Children who have IR and hyperinsulinemia and did not develop type II DM are still at risk for other complications of IR such as dyslipidemia, early atherosclerosis, hypertension, progressive obesity (especially centripetal type), fatty liver infiltration, hypercoagulation, skin disorders such as acanthosis nigricans and increased skin tags, Polycystic ovary syndrome, renal impairment in the form of focal segmental glomerulosclerosis, and an increased risk of cancer[64]. Accordingly, IR should not be considered a benign condition even in the absence of DM type-II.

Although obesity (especially centripetal type) could lead to IR, genetically based IR may also provoke the progression of obesity. This finding explains why IR was observed in some non-obese lean sisters and brothers of obese children with IR, indicating IR was the primary disorder[65]. Genes accountable for IR could interact with various environmental factors (such as increased caloric and fat intake augmented with decreased physical activity), resulting in the development of IR, which increases secretory demand on β-cells, causing hyperinsulinemia[66]. Inulin serves as an anabolic hormone responsible for proper nutrient storage following meal ingestion. It also inhibits lipolysis, promotes fat storage, and consequently induces obesity[67]. Certain ethnicities are known to have very high circulating insulin levels, such as Pima Indians, Chinese children, and African American children have a higher prevalence of obesity[68-70]. However, this observation is unique for children and cannot be extended to adults.

Central obesity (with a high waist/hip ratio), a common IR finding, increases the risk for early atherosclerosis, premature coronary artery disease, stroke, and early death. Waist circumference strongly positively correlates with cardiovascular morbidity, BMI, and body fat percentage. The high risk of visceral obesity is due to increased free fatty acid efflux originating from the visceral fat, more glucocorticoid receptors, higher visceral fact concentrations of glucocorticoids, and the low leptin hormone levels with its protective effects compared to the subcutaneous fat[71-73]. As mentioned before, IR increases the risk of obesity, especially the centripetal type, and in turn, central obesity increases the risk of IR and consequently increases cardiovascular risk. A population-based study by Ikezaki *et al*[74] showed that the reduced cardiovascular risk observed in the Japanese population compared to the American Caucasian population was linked to the considerable population variations in IR.

IR causes many metabolic changes, including hypertriglyceridemia, reduced serum protective high-density lipoproteins (HDL) cholesterol levels, increased atherogenic low-density lipoprotein (LDL) cholesterol particles, and low level of sex hormone-binding globulin (SHBG). Hence, it increases the atherogenic dyslipidemia status and the risk of early atherosclerosis[75]. Hyperinsulinemia also increases renal sodium retention augmented with the IR-induced sympathetic nervous system overactivity and fast vascular smooth muscle growth[76]. IR and hyperinsulinemia also induce early endothelial dysfunction preceding the formation of atherosclerotic plaques, starting the process of atherosclerosis during childhood[77]. These IR-induced changes may precipitate the development of early hypertension. Davis *et al*[78] showed that childhood and current cardiovascular risk factors especially total cholesterol in both males and females and BMI in females, are correlated with a higher carotid intimal-medial thickness in adulthood. In adulthood, coronary artery calcifications are also associated with high blood pressure and reduced protective HDL cholesterol levels measured during childhood. Lipid streaks can be found in the aortic wall in children as young as three years and in the carotid arteries by adolescence[79].

Fatty infiltration of the liver is a common problem observed in patients with IR, which could progress with time to end with inflammation (steatohepatitis), fatty liver fibrosis, and even liver cirrhosis and failure. With the increasing worldwide prevalence of obesity, the non-alcoholic fatty liver has become the most common pediatric liver disease. According to Schwimmer *et al*[80], the rate of fatty liver can reach up to 38% among children with obesity. Peng *et al*[81] showed that the prevalence of non-alcoholic steatohepatitis in children with obesity is strongly linked to high BMI-standard deviation score, gender, uric acid, waist circumference, body fat, IR, and hyperuricemia. Fatty liver infiltration is usually asymptomatic for many years. Still, it can be expected when liver enzymes rise, such as alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transferase, which may indicate hepatic fat accumulation. The aspartate aminotransferase/alanine aminotransferase ratio is generally less than one, but this ratio rises as fibrosis progresses[82]. It is commonly diagnosed as an incidentally by abdominal ultra-sound during an examination for other reasons[83]. Consequently, children with IR and obesity should be monitored to detect liver disease early.

IR and obesity commonly present with pseudo-endocrinal hyperfunction due to a decrease in hormonal binding proteins suggesting a common underlying controlling mechanism. Decreasing cortisol-binding globulin (CBG) causes an increase in free cortisol level, which causes the manifestations of Cushing's syndrome (pseudo Cushing's syndrome), which could overlap with the manifestation of MS. Fernandez-Real showed that the level of CBG is negatively correlated with insulin level[84]. Insulin-like growth factor-I binding protein (IGFBP-1) decreases in IR, causing an increase in free but not the total IGF-I. The increase in free IGF-1enhances the glucose-reducing effect of insulin, causing microvascular complications and manifestations of pseudo-acromegaly (acromegaloidism) with linear and acral growth (acromegaloid features) and signs suggestive of excess GH and normal levels of GH and total IGF-1[85]. IGFBP-1 Levels are negatively correlated with the severity of IR, while IGFBP-3 Levels correlate directly with hyperinsulinism[86]. Hyperinsulinemia also enhances linear growth by upgrading the skeletal IGF-1receptors, augmented by the increased free IGF-1 action. Pseudoacromegaly can also result from ghrelin gene polymorphism, which can induce obesity and IR[87].

IR also causes a reduction of thyroid-binding globulin plasma levels, confusing with the presence of hypothyroidism, and consequently, unnecessary treatment for hypothyroidism. In the presence of low TBG, we should consider other thyroid function tests, including thyroid-stimulating hormone and total and free thyroxine, and triiodothyronine. On the other hand, detecting hypothyroidism in IR and obesity is crucial. It could be the underlying cause of IR as thyroid hormones have a significant impact on glucose metabolism[88]. SHBG is a hepatic-produced protein that adheres to sex hormones with high specificity and affinity in males and females. SHBG is negatively correlated with fasting insulin levels and BMI. Sørensen *et al*[89] showed that puberty is associated with low SHBG levels, explaining the increased cardiovascular risk during puberty. They also showed that SHBG is a potent predictor of insulin sensitivity and metabolic risk during puberty. Chen *et al*[90] found that SHBG is a significant objective element of IR indices and can be used as an adequate positive indicator for IR in patients with polycystic ovary syndrome (PCOS), especially those who are overweight/obese. Reduced SHBG levels increase the free testosterone available to the tissues leading to manifestations of hyperandrogenism such as hirsutism and acne, even in the presence of normal total testosterone levels. Consequently, it induces progressive ovarian pathology, anovulation, and the characteristics features of PCOS[91].

The increased free androgens increase their aromatization and conversion into estrogens, increasing the incidence of adipo/gynecomastia in male adolescents with more GH production and increasing longitudinal bone growth[92]. Littlejohn *et al*[93] described a series of four girls with severe IR, which showed nearly all the features of pseudo-endocrine hyperfunctions associated with IR. The girls had severe prepubertal obesity due to severe IR, followed by the appearance of early childhood pseudo Cushing's syndrome, then manifestations of pseudo-acromegaly, which herald adolescent polycystic ovary syndrome.

People with overweight or obesity commonly have vitamin D deficiency even in different age groups and ethnicity. As vitamin D is fat-soluble, and there is a marked increase in fat mass in patients with obesity, there is a volumetric dilution causing a relative deficiency. Consequently, people with obesity need higher supplemented doses to maintain normal serum levels of 25-hydroxyvitamin D than people with average weight[94]. Lind *et al*[95] showed that serum levels of 25-OH-vitamin D are negatively correlated with fasting insulin and positively correlated with insulin sensitivity. They also showed that IR is associated with low 25-hydroxyvitamin D3 levels. Vitamin D is essential for the normal secretion of insulin.

Consequently, vitamin D deficiency aggravates the metabolic derangement in IR and obesity. Vitamin D binding protein (VDBP) binds to about 90% of the total vitamin D while only 1% of vitamin D metabolites is present in a free unbound form. VDBP is a macrophage-activating factor with a potent tumor growth inhibitor and strong anticancer activity. Ashraf *et al*[96] showed that VDBP levels are inversely correlated with IR and hyperinsulinemia. Consequently, low vitamin D status is associated with higher risks of several cancers in patients with obesity[97]. Meanwhile, Pratley *et al*[98] showed that VDBP polymorphism is connected to the increased risk of diabetes in Pima Indians.

IR-related obesity characterizes by increased markers of inflammation like CRP and erythrocyte sedimentation rates. The inflammation is more common in girls than boys who have BMI more than 95th percentile[99]. CRP levels correlate significantly with BMI and adipose tissue mass in the young adult population[100]. The visceral obesity, systemic inflammation, and cellular dysfunction associated with IR are significant cardiovascular risk factors. When started in childhood and persist until adulthood, it induces various chronic cardiovascular diseases such as atherosclerosis, systemic hypertension, and coronary artery diseases[101]. However, CRP elevation and degree of inflammation could improve with dietary modification and more grain consumption[102]. As asthma and obesity are associated with systemic inflammation, increased pro-inflammatory state, and the effects of increased leptin levels on Th1 cytokine responses, there is an increase in asthma prevalence among children with obesity, especially during puberty[103]. Castro-Rodríguez *et al*[104] showed that BMI positively correlates with the prevalence of asthma in both boys and girls. They also showed that girls who become overweight or obese between 6 and 11 years are seven times more likely to have asthma at age 11 or 13. Consequently, weight reduction helps to improve pulmonary functions and asthma symptoms and reduce the need to use rescue bronchodilators and the frequency of asthma exacerbations[105]. Obstructive sleep apnea, a common complication of obesity, can increase IR. IR is expected to present when children with obesity have obstructive apnea-hypopnea index ≥ 4.9[106].

High insulin levels in IR stimulate insulin and IGF-1 receptors in human keratinocytes, causing the increased thickness of the stratum corneum with hyperpigmentation in a racially dependent manner (Acanthosis Nigricans). The posterior region of the neck, axillae, antecubital fossae and groins are the most common affected sites. In contrast, other flexural areas, sub-mammary region, umbilicus, elbows, knuckles, and, in extreme cases, the entire skin are less commonly involved. The degree of IR and the insulin blood levels positively correlate with the severity of acanthosis nigricans[107-109]. Özalp Kızılay *et al*[110] showed that IR is more predictive of psychiatric illness than obesity-related metabolic comorbidities. Consequently, it is crucial to assess the presence of psychiatric malfunctioning in obese children, particularly those with IR. We highly recommend routine screening to identify the presence of psychiatric disorders in children with obesity.

**CLINICAL PRESENTATION**

Appropriate history and comprehensive clinical examination provide a lot of information that helps to diagnose IR.

**Patient Medical History**

IRS is commonly associated with dyslipidemia, obesity, skin changes, atherosclerosis, hypertension, DM type-II, hyperandrogenism, and polycystic ovarian syndrome. The clinical presentation of IR is variable and depends on its etiology and severity. History can elaborate on the presence of high-risk IR. Maternal history of gestational DM, preeclampsia, or intrauterine growth restriction could expect the development of IR, especially in obese offspring. The large or small birth weight for gestational age is also a significant risk factor for IR. Microcephaly, with head circumference less than the 10th centile at birth, may indicate significant intrauterine growth retardation, which could be a sign of genetic causes of IR, or the growth restriction itself could induce IR[111,112]. It is critical to evaluate preceding anthropometric measurements using appropriate growth charts and give attention to the catch-up growth in smaller babies. Particular attention should be given to recent rapid weight gain, specifically if be associated with dysmorphic features. History of cold intolerance, easy bruising, generalized weakness, and easy fatigability could indicate the presence of other endocrine disorders such as hypothyroidism or Cushing's syndrome[113].

The onset and duration of obesity are also crucial to predict IR's presence and complications. Infants and children who developed obesity and significant weight gain before the age of five and particularly in the 1st year of life are more liable to have genetic causes for IR and obesity. Early development and a longer duration of obesity predict an adverse metabolic profile of the affected child[114]. However, all children with overweight or obesity have IR, and not all children with IR are overweight or obese[115]. The dietary history is also essential considering the overall caloric intake, considering the food elements that significantly impact the weight gain and the metabolic pattern in the child with overweight or obesity. Taking a good dietary history is mandatory to identify the dietary components that could lead to obesity development and, at the same time, can give a clue to improve the metabolic derangement even without significant weight loss[116]. At the same time, the sleeping pattern is equally essential to dietary history. The duration of the sleep, the sleep pattern, and the presence of sleeping disorders should be addressed. OSA is a frequent disorder observed in children with obesity, which further increases IR due to various pathologic mechanisms such as tissue hypoxia and sympathetic activation[56]. Therefore, children with obesity and snore, mainly when mouth breathing, should be screened for the presence of OSA with polysomnography[117].

Good medical history should address the lifestyle, sedentary behavior, and the child's physical activity. With the overuse of the media, especially during the current coronavirus disease 2019 pandemic and spending more and more media time, including television, online teaching, computer gaming, and smartphone use, we expect a significant rise in the rate of obesity and consequently IR[118]. However, any physical activity, even non-weight reducing activity, may provide a beneficial metabolic effect on the body fat composition and improve the general body insulin sensitivity. Therefore, any degree of physical activity should be encouraged[119]. As many medications significantly impact insulin sensitivity, a medication history is mandatory while managing a child with either obesity or suspected IR[120]. We should ask about any medications/drugs that affect appetite, glucose, or lipid metabolism. As mentioned before, some psychotropic medications such as Clozapine, Olanzapine, and Risperidone, corticosteroids, growth hormone therapy, some antihypertensive drugs such as beta-blockers, and diuretics as thiazides, antiepileptics as Valproate, and some common antineoplastic drugs as Tacrolimus, Cyclosporine A, and Sirolimus[121]. As IR has many genetic causes, positive family history of similar conditions, obesity, DM type II, or other forms of metabolic disorder is common.

**Physical Examination**

Adequate physical examination is mandatory as it helps assess the presence and the severity of IR and the underlying cause. General appearance can hint about the underlying lesion, especially in the presence of dysmorphic features and pseudo-acromegalic features (with suppressed GH levels), which could signify the presence of genetic or secondary causes of IR. The anthropometric examination is essential during any child examination, particularly when overweight or obese, is expected. Weight, height, BMI, mid-arm, and waist circumference should be measured and plotted on the appropriate charts and growth curves. Height is measured to the nearest 0.5 cm, while the body mass is measured to the nearest 0.1 kg using a standard stadiometer. The waist circumference is measured using a cloth tape at the end of normal expiration to the nearest 0.1 cm at the midpoint between the uppermost lateral border of the right iliac crest and the lowest rib. Children are considered overweight when their BMIs are higher than the 85th percentile for age and sex, or BMI equals to or more than 25 kg/m2. They are considered obese with BMIs higher than the 95th percentile or BMI equal to or more than 30 kg/m2[122]. However, not all children with obesity have IR, but most children with BMIs more than 35-40 kg/m2 have IR[123]. Fat distribution, especially the abdominal fat, impacts the development of IR and consequent non-alcoholic fatty liver disease in obese children. So, we should evaluate the intraabdominal type (apple-shaped) *vs* peripheral fat (gluteal-femoral, extremity, or pear-shaped) and document waist circumference and waist/hip ratio. The body fat percentage can be assessed using different methods, such as an X-scan bioelectrical body composition analyzer[124]. Tall stature may indicate the presence of underlying endocrine or chromosomal disorders, *e.g.*, Klinefelter syndrome.

The blood pressure is measured using an appropriately sized cuff after at least 5 min of rest, preferably with an automated instrument in a seated position. At least two readings are measured, and the average value is used for analyses and adjusted for age, sex, and height. Occasionally, we may need a 24-h ambulatory blood pressure evaluation. Blood pressure could be high in some endocrine disorders that may induce IR, such as Cushing syndrome. Giordano *et al*[125] found an association between a decrease in nocturnal blood pressure and insulin levels (as a measure of IR), regardless of obesity or diurnal blood pressure levels. The pulse also should be evaluated for any resting tachycardia. Flanagan *et al*[126] found that the insulin sensitivity in the young adult correlated with cardiac sympathovagal balance in males but not in females, suggesting the effect of gender on the autonomic modulation of IR. We should also search for signs of heart failure to rule out obesity-induced cardiomyopathy[127]. The examiner should also ask about any signs of respiratory distress (for underlying bronchial asthma), expiratory wheezing, and snoring, indicating upper airway obstruction and possible OSA.

Abdominal examination is a crucial part of child examination for IR. Abdominal obesity is diagnosed when waist circumference equals to/more than 90th percentile for age and gender. After adjusting for BMI percentile, waist circumference significantly correlates with total and abdominal visceral fat and insulin sensitivity. Some studies revealed that BMI and waist circumference together are superior predictors of metabolic risk than only one of them[128,129]. It is also essential to look for striae and detect organomegaly. Hepatomegaly may present as a sign of congestive heart failure due to obesity-induced cardiomyopathy or steatosis and non-alcoholic steatohepatitis[130]. Abdominal pain could occur as a side effect of metformin treatment.

Skin is commonly affected by IR. Obesity, IR, or DM indicators may include hypo/hyperpigmentation, acanthosis nigricans, abdominal skin striae, skin tags, fatty breast (adipomastia) in males, hirsutism, acne, frontal balding, and signs of virilization in females. Higher insulin levels could associate with premature pubarche. Premature pubarche and virilization in girls are potential antecedents of PCOS. It is due to increased insulin levels with a causal relationship between high insulin levels and hypersecretion of the adrenal and/or ovarian androgens[131]. Acanthosis nigricans is a darkly pigmented, velvety, hyperkeratotic, papillomatous skin lesions in body folds such as the skin of the neck or axilla. The presence of acanthosis nigricans is due to acanthocytes' exposure to hyperinsulinemia, interacting with insulin-like growth factor-1 receptors on these cells[132,133]. Multiple skin tags are more sensitive than acanthosis nigricans in identifying abnormal glucose/insulin metabolism. Multiple skin tags should increase suspicion of increased risk of IR or hyperinsulinemia[134]. Examinations of the extremities for strain and deformities should be done as genu varum and other lower extremity postural defects are common in children with overweight or obesity[135].

**LABORATORY DIAGNOSIS OF IR IN CHILDREN**

Diagnostic standards for IR in children are not yet established due to various causes, including different techniques to measure IR, insufficient patient size, and lack of adequate longitudinal long-term pediatric studies. Thorough evaluation of impaired sensitivity and responsiveness to the insulin thus needs an assessment of insulin dose-response curves. Hyperinsulinemia is defined when the fasting insulin level is > 15 µU/mL, or peak insulin level is > 150 µU/mL or > 75 µU/mL at 2 h after the oral glucose tolerance test, which may indicate IR[17].

**DIRECT MEASURES OF INSULIN SENSITIVITY**

Direct measures of insulin sensitivity are valid and reliable for the measurement of insulin sensitivity. They include the hyperinsulinemia euglycemic glucose clamp (HEGC) and the insulin-suppression test (IST). These tests are time-consuming require intravenous infusions and frequent sampling. It is troublesome for participants, is expensive, and needs a research setting.

The HEGC is the gold standard to assess IR. However, the frequently sampled intravenous glucose tolerance test (FSIVGTT), and oral glucose tolerance test (OGTT) are also valid and often used methods as they are more simple and more accessible to be used[16]. In HEGC, the insulin is infused intravenously after overnight fasting at a constant rate (5-120 mU/m2/min), increasing and maintaining a steady state of systemic insulinemia, which induces increased glucose uptake by the peripheral tissues and suppresses the hepatic glucose production, causing hypoglycemia. Consequently, a bedside glucose analyzer regularly monitors blood glucose levels at 5-10 min. An intravenous glucose 20% infusion at variable rates occurs to maintain (clamp) glucose levels within the normal range to maintain a euglycemic state. The glucose infusion rate is adjusted and directly proportional to insulin sensitivity to maintain the euglycemic state. The more glucose is needed to maintain the euglycemic state, the more the body is sensitive to the insulin effect. We need less glucose infusion to maintain the euglycemic state in IR. Caution should be taken to avoid insulin-induced hypokalaemia, and potassium phosphate infusion should be given to prevent hypokalaemia[136]. This test has the advantage of directly measuring the whole-body tissues’ glucose disposal at a certain level of insulinemia but has the disadvantage of technical difficulties[137].

TheIST also directly evaluates metabolic insulin sensitivity/resistance to the exogenous insulin after suppressing endogenous insulin production. First, we suppress the endogenous secretion of insulin and glucagon by giving intravenous infusion somatostatin (250 μg/h) or octreotide (25 µg bolus, followed by 0.5 µg/min) after overnight fasting. At the same time, we infuse both insulin (25 mU/m2/min) and glucose (240 mg/m2/min) in the same vein. We continuously monitor glucose and insulin from the contralateral arm every 30 min for 150 min, after that, every ten minutes till the end of the third hour. We usually reach the steady-state plasma insulin and steady-state plasma glucose (SSPG) between 150-180 min of the test. We evaluate the sensitivity of the tissue to the exogenous insulin by measuring SSPG levels. The higher the SSPG levels are, the lower the tissue sensitivity to the insulin is, and the lower the SSPG levels are, the higher the insulin sensitivity is[138]. This test provides a highly reproducible direct measure of metabolic actions of insulin and is less technical dependant than HEGC. However, applying IST in the clinical setting is not practical[139].

**INDIRECT MEASURES OF INSULIN SENSITIVITY**

Minimal model analysis of FSIVGTT provides an indirect estimate of metabolic insulin sensitivity/resistance, acute insulin response, and disposition indexes. After an overnight fast, we inject a bolus of glucose (0.3 g/kg body weight) by intravenous infusion over 2 min starting at time 0; we collect serial blood samples for glucose and insulin level until three hours after the test. The test assesses insulin sensitivity/resistance by a computed mathematical assessment of glucose and insulin dynamics. It examines the plasma glucose dynamics and the glucose per se to promote its disposal and suppress the hepatic glucose production without an increased insulin effect. It is easier than the glucose clamp method[140].

OGTT is an easy, simple test commonly used in clinical practice, especially during early pregnancy, to diagnose glucose intolerance and type 2 diabetes. However, it tests the glucose tolerance and the ability of the body to dispose of the orally ingested glucose and not IR. We give a standard 75 g of glucose orally after an overnight fast. Then blood samples to determine glucose and insulin levels are taken at 0, 30, 60, and 120 min[141]. OGTT provides the benefits of having fewer blood samples with high correlations with the euglycemic hyperinsulinemic clamp in adult studies but not well studied in the pediatric age[142].

**SIMPLE SURROGATE INSULIN SENSITIVITY/RESISTANCE INDEXES**

These indexes were created to simplify the measurement of insulin sensitivity. They depend on estimating the fasting blood glucose and insulin levels after overnight fasting. Fasting induces a steady basal state where insulin and glucose plasma levels should be maintained in the normal ranges in a healthy human. So, these indexes reflect the basal insulin secretion by pancreatic β cells and the hepatic insulin sensitivity/resistance. These indexes use a specific mathematical formula that corrects the individual variabilities in glucose and insulin secretion and clearance. However, these indexes are insensitive, lack standardization, and cannot define universal cut-off points for IR[143]. The most common indexes used are the homeostasis model assessment (HOMA), quantitative insulin sensitivity check index (QUICKI), insulin sensitivity index, ISI (0, 120), and adipose tissue IR index (Adipo-IR).

HOMA assumes a feedback loop between pancreatic β-cell and liver. This means that pancreatic β-cell is stimulated by glucose to secrete insulin which in turn stimulates the glucose uptake by the liver and inhibits hepatic glucose production (HGP). In IR, there will be suppression of the HGP. HOMA score is calculated from the following formula: [Fasting glucose (mg/dL) × Fasting insulin (µU/mL)]/405.

An important limitation of the HOMA score is that it indicates the fasting steady-state of pancreatic β-cell and not the actual dynamic state of β-cell Insulin secretion. There is insufficient evidence to support HOMA cut-off values frequently used to identify IR in pediatric studies[144].

QUICKI is also derived from fasting blood glucose and plasma levels. It provides a consistent, reproducible, and precise insulin sensitivity index with outstanding positive predictive value. It uses the following formula: 1/[log of fasting insulin (µU/mL) + log of fasting glucose (mg/dL)].

Adding the log of fasting glucose to the log of fasting insulin provides a reasonable correction and better linear correlation with insulin sensitivity by the HEGC method both in diabetic and non-diabetic patients. It is an appropriate and practical test. It can be used in extensive epidemiological or clinical research studies and help follow changes after therapeutic interventions[145]. ISI (0, 120) is developed by Gutt *et al*[146] and uses the insulin and glucose concentrations both fasting (0 min) and at 120 min post- OGTT. It can screen both obesity and glucose intolerance and correlate well with the euglycemic hyperinsulinemic clamp.

Consequently, it is superior to other indices of insulin sensitivity, such as the HOMA formulae[146]. Adipo-IR is obtained by measuring the fasting level of FFA and insulin. Adipo-IR is well correlated with adipose tissue insulin sensitivity. Adipo-IR is well correlated with and a significant predictor of MS. However, its predictive value is affected by age and physical fitness[147].

**IR SCREENING**

There is no rationale for screening children for IR, even among children with obesity. Considering that IR in children with obesity increases cardiovascular risks, screening for IR is valid. However, any screening program needs accurate, reliable, easy, and reproducible tests. Screening tests for IR also need to be adjusted for ethnic groups, genders, and pubertal stages. Using lengthy and costly methods such as HEGC or IST is impractical. At the same time, tests that depend on fasting insulin as a screening test are unreliable measures of insulin sensitivity[148].

Meanwhile, there is no definitive recommended pharmacological therapy for isolated IR. Accordingly, it will be wiser to screen and actively manage children with obesity rather than screening for IR[149]. Among the tools that can screen for obesity and IR is ISI (0, 120). It has good predictive value for obesity, IR, DM, and cardiovascular disease (CVD) events. However, it needs more evaluation, particularly in the pediatric age. Rutter *et al*[150] showed that ISI (0, 120) and the MS, not the HOMA-IR index, could independently predict CVD. They also showed that MS might not catch all the CVD risks related to IR. Moreover, Adipo-IR may serve as a useful screening tool to detect IR, especially in those with a high risk of developing DM type-II, even in the absence of clinical risk factors such as obesity or impaired glycemia[25].

**PREVENTION OF IR**

To prevent future IR, we should target all the factors that could help the development of IR in the future, such as factors that affect fetal growth and development as maternal obesity, pregestational and gestational DM, maternal smoking, especially during pregnancy, maternal undernutrition, and premature delivery[2]. Exclusive breastfeeding until at least four months and continuing until the age of two has a significant impact on reducing child obesity and IR in the future[151,152]. However, there are no sufficient data about the direct effect of breastfeeding in IR prevention. However, its role in obesity prevention is solid. The pancreatic β cells differentiate during fetal life. Still, their maturation and ability to secrete insulin in response to glucose stimulation are modulated during the early postnatal life and modified by the weaning practice[153]. Consequently, proper weaning timing and technique are essential contributors to preventing childhood obesity and IR[154,155]. As antibiotic treatment early in life could increase the risk of obesity, co-administering prebiotic with antibiotics could reduce obesity risk, as demonstrated by Klancic *et al*[156].

Obesity is strongly linked to IR either with a cause-result effect, dietary interventions to prevent obesity could help reduce the prevalence and severity of IR. Increased intake of saturated fat is associated with diminished insulin sensitivity in children. However, we may notice some ethnic differences between children[52]. On the other hand, the intake of a healthy diet low in saturated fat and cholesterol starting at the age of 7 mo is associated with a positive impact on IR at the age of nine[157]. Van Hulst *et al*[158] also showed that reducing saturated fat and raising fruit and vegetable intakes during childhood may enhance insulin sensitivity during puberty. Improving physical fitness in toddlers, preschool, and school children, especially those at high risk for obesity, is an effective preventive way to prevent obesity and IR. Even when not associated with weight reduction, physical activity prevents and even improves IR[159].

**TREATMENT OF IR IN CHILDREN**

The main aim of the treatment of IR in children is to prevent the progression of compensated IR to decompensated IR, enhance insulin sensitivity, and treat possible complications. There are three main lines for treatment: Lifestyle and behavior modification, pharmacotherapy, and surgery (Figure 1).

***Lifestyle and behavior modification***

Lifestyle and behaviour modification is the cornerstone in IR prevention and management. It includes dietary intervention and increasing physical fitness and activity. Exercise may have the upper hand and a more substantial impact in improving insulin sensitivity than the isolated weight reduction[160]. There is a direct relationship between the daily step number the subject does with the blood level of IGF-1 and an inverse relation with high sensitivity CRP. So, physical activity can modulate IR and related inflammation, whereas sedentary time affects fatty acid-binding proteins[161]. Despite the apparent benefits of physical fitness on insulin sensitivity, the exact mechanism is unclear, mainly that improvement in insulin sensitivity occurs earlier than or even without actual loss of body weight[162]. There are not enough studies to compare the different degrees of exercise intensities or the effects of single-session exercise *vs* a training regimen on insulin sensitivity. Also, there is no strong evidence about the optimal exercise form that produces maximum effects on insulin sensitivity. However, a combination of aerobic and resistance exercise training regimens improves insulin sensitivity[163]. Children with IR should be aggressively involved in an exercise program, such as swimming or walking for 30-40 min for most weekdays to provoke glucose entry into the muscles without insulin involvement. Pedometers can be used to monitor their physical activities. Continuation of physical exercise is of utmost importance as cessation of exercise after initial improvement of insulin sensitivity is associated with reverting to the pre-exercise levels (a condition known as rebound phenomenon with higher IR)[164].

***Dietary intervention***

Dietary intervention improves insulin sensitivity in children and adolescents through weight reduction and other unknown mechanisms. Avoiding increasing dietary fat intake, reducing saturated fat intake, increasing unsaturated fat (*e.g.*, olive oil and other vegetable oils) intake, increasing vegetable and fruit consumption, and reducing sugar intake are the main elements for the dietary intervention to improve insulin sensitivity[101]. Adherence to the Mediterranean diet, which incorporates vegetables and olive oil, avoiding the intake of highly processed food and sugar-sweetened beverages, helps to reduce the body weight and improve insulin sensitivity[165-167]. As mentioned before, intake of a high whole-grain diet or dietary fibres improves insulin sensitivity and help to reduce the body weight and BMI in children, adolescents, and adults[168,169]. Probiotic supplementation showed significant improvement in IR indicators in animal studies. It improves inflammatory and oxidative markers, lipid profile, short-chain fatty acids production and microbiota structure. These changes could result from strengthening the intestinal barrier and enhancing the immune system and metabolism. Consequently, adding probiotics to a healthy diet and changing the lifestyle to be more active with/without medications could help to attenuate IR[170,171]. Meanwhile, vitamin D supplementation positively improves insulin sensitivity and cardiovascular and metabolic risk factors in children with obesity[172].

**Pharmacologic Management**

There is no specific pharmacologic management for IR. However, pharmacologic treatment is occasionally needed to augment lifestyle management, especially in significant childhood obesity. Because of the severe side effects that could rarely happen, pharmacologic therapy should be sued only in selected cases. We should consider the patient's age, BMI, and associated comorbidities when considering pharmacotherapy. Close monitoring is also required as long-term effects still need more studies[173,174]. Pharmacotherapy involves two main categories: Drugs that decrease fasting plasma glucose and adjust insulin concentrations, lipid-lowering drugs, and drugs that enhance weight loss.

***Drugs that decrease fasting plasma glucose and adjust insulin concentrations***

The Biguanide-derived metformin is the drug of choice in treating DM type-II in children above ten years. It also showed documented efficacy in improving IR through reducing the body weight, BMI, fasting plasma glucose, and insulin levels. It enhances insulin binding to its receptor even in the presence of receptor autoantibodies (IRS type B) through phosphorylation augmentation and increasing insulin receptor-tyrosine kinase activity[175]. It increases the peripheral tissues glucose utilization by enhancing phosphoinositol 3-kinase at the receptor level, potentiating glucose transporters GLUT1 and GLUT4 isoforms translocation to the cell membrane of various tissues[17]. It is also effective even in the presence of insulin receptor mutation[17]. Recent studies also showed that pre-prandial metformin could acutely reduce blood glucose levels *via* intestinal glucose transport inhibition and increase intestinal glucagon-like peptide-1[176]. It also reduces the food intake with a further reduction of the body weight, fasting glucose, glycated hemoglobin (HbA1c), insulin, and cholesterol levels. These effects help to improve BMI, body fat composition, lipid profile, and consequently IR. However, although metformin improves insulin sensitivity, it is not indicated in cases with isolated IR[177]. According to the 2017 guidelines endorsed by The Pediatric Society, metformin should be used in selected pediatric patients such as girls with obesity, polycystic ovaries, and glucose intolerance[178]. When using metformin, gradually increased doses can minimize the various gastrointestinal side-effects. Vitamin B12 deficiency could result especially with the long-term use of Metformin, and close monitoring may be required[2].

Incretins are a group of gut-derived metabolic peptide hormones that are promptly secreted in reaction to a meal and promote the reduction of blood glucose levels by augmenting insulin secretion from pancreatic β-cells and inhibiting glucagon release from the alpha cells, a blood glucose-dependent mechanism. There are two main categories of incretins: the intestinal glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide known as gastric inhibitory peptide. Incretins are rapidly deactivated by the enzyme dipeptidyl peptidase-4 (DPP-4)[179]. DPP4 inhibitors such as linagliptin are relatively newly discovered glucose-reducing drugs which antagonize the inhibitory effects of endogenous incretins on insulin secretion, causing increasing insulin secretion in response to blood glucose levels. DPP4 inhibitors improve fasting and post-prandial blood glucose and HbA1c levels[180]. Linagliptin also has protective effects against diabetes-induced macrovascular and microvascular complications. However, Linagliptin is still an investigational drug that has not yet been approved in children and adolescents due to insufficient clinical studies[181].

GLP-1 also reduces the inflammatory cytokine release, inhibits macrophage infiltration into the fatty tissue, the liver, and the vascular wall, and reduces IR-induced chronic inflammation[182]. GLP-1 inhibits food intake through actions in the hypothalamus, including the paraventricular nucleus[183]. Consequently, GLP-1 analogs, such as Liraglutide, could enhance insulin sensitivity and reduce body weight in patients with IR. Danne *et al*[184] showed that Liraglutide use in adolescents with obesity has a safety and tolerability profile like that observed in adults.

Sodium-glucose cotransporters (SGLT) are a group of glucose transporter responsible for apical sodium and glucose transport across cell membranes. They are responsible for the absorption of glucose and galactose in the gastrointestinal tract (SGLT1) and reabsorption of 90% of filtered glucose in proximal renal tubules (SGLT2)[185]. Sotagliflozin (an oral potent dual SGLT1 and SGLT2 inhibitor) effectively improves the glycaemic state by reducing HbA1c, post-prandial blood glucose, body weight in adults with DM type-I and type-II[186]. An animal study showed that the selective SGLT2 inhibitor Empagliflozin was effective as monotherapy or when combined with DPP-4 inhibitor in improving IR in mice with proper glycaemic control[187]. However, we need more consistent data to determine its actual benefits and adverse effects on adults and children with IR.

***Lipid-lowering drugs***

The PPAR agonists regulate energy (glucose and lipid) metabolism, inflammation, and cell proliferation. They are of three groups: alpha, beta/gamma, and delta used to treat symptoms of MS, primarily by reducing triglycerides and blood sugar[188]. PPARα agonists are the main target of fibrate drugs (clofibrate, gemfibrozil, ciprofibrate, bezafibrate, and fenofibrate). They decrease triglyceride levels *via* PPARα transcription factor, mainly in the liver, inducing fatty acids oxidation, and controlling gluconeogenesis and amino acid metabolism. They are primarily indicated in cholesterol disorders and hypertriglyceridemia[189]. They can also reduce the inflammatory markers such as fibrinogen, CRP, plasminogen activator inhibitor-1, IL-6, and vascular cell adhesion molecule-1 expression[190]. When combined with statins, care should be taken as they may induce a severe form of rhabdomyolysis. Children with severe hypertriglyceridemia (> 400 mg%) can use fibrates to prevent pancreatitis with high tolerability[191]. The PPAR-γ agonists are ligand-activated transcription factors that treat DM and other diseases with IR[192]. PPAR-γ agonists (*e.g.*, pioglitazone and rosiglitazone) can decrease adhesion molecules and inflammatory proteins. They also have lipid-lowering effects through enhancing lipid oxidation, reducing adipocytes' free fatty acid secretion, decreasing intramyocellular lipids, and improving muscular IR. They also decrease 11 beta-hydroxysteroid dehydrogenase type 1 and testosterone levels in IR females[193,194]. Animal studies showed a possible role of PPAR-γ agonists in improving pulmonary inflammation, especially that present in asthma[195].

***Weight reducing drugs***

Weight reduction by 5%-7% is enough to decrease the diabetes risk by 58% in high-risk persons. Statins are commonly used drugs to reduce body weight. Orlistat is a potent inhibitor of gastric and pancreatic lipase enzymes, y reducing the absorption of cholesterol and triglyceride from the gastrointestinal tract. Orlistat improved lipid profile and led to faster glycaemic control and IR parameters. It also improves retinol-binding protein-4 (RBP-4) and visfatin. RBP-4 is known to be associated with an increased cardiovascular risk. Visfatin is a novel adipokine known to have neuroprotective effects against cerebral ischemic injury[196]. Orlistat can enhance insulin sensitivity in children and adolescents. However, it should be used wisely and in selected cases in this age group[197,198]. Sibutramine is a weight-reducing drug used to treat obesity mainly by its appetite-suppressing effect. Care and awareness about the loss of its effectiveness and the possible detrimental adverse effects should be given[199]. Statins reduce hepatic cholesterol synthesis by inhibiting the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, consequently increasing the hepatocyte uptake of LDL decreases the atherosclerosis progression. Even though statins are safe and well-tolerated in children, their long-term safety is not firmly established in this age group[200].

***Other drugs***

L-carnitine has been used for several years as adjuvant therapy in oxidative stress. A meta-analysis by Xu *et al*[201] showed that L-carnitine is beneficial and effective in treating patients with IR. Children with severe dyslipidemia and IR with a high risk for pancreatitis may get benefit from using daily low dose Acetylsalicylic acid (aspirin 81 mg/d) to inhibit arachidonic acid conversion to prostaglandins G2 and H2, known precursors of thromboxane, and consequently decrease the risk for serious cardiovascular events[202].

**Surgery**

Bariatric surgery is presently the most successful approach for sustained and significant weight loss and recovery of the associated comorbidities[203]. Bariatric surgery is beneficial in improving diabetes through the increase in β-cell function and/or mass, increasing insulin secretion, and decreasing IR[204]. Numerous researchers have investigated IR and β-cell function changes after different kinds of bariatric procedures. A meta-analysis by Rao *et al*[205] showed that gastric bypass, biliopancreatic diversion, and sleeve gastrectomy produce an early decrease in IR (within two weeks) through yet unknown mechanisms. Sleeve gastrectomy had an earlier reduction in IR than gastric banding. A Dutch study showed increased acceptance of bariatric surgery by the pediatricians, parents, and adolescents as a therapeutic in children and adolescents with severe obesity who do not respond to lifestyle intervention[206]. However, intestinal bypass surgery in children should possibly only be used in cases of potentially life-threatening complications of obesity such as IR, OSA, dyslipidemia, hypertension, non-alcoholic fatty liver diseases, and bone and joint problems[207].

**Treatment of Specific cases with IR**

The treatment can be individualized in certain pathological conditions.

**Congenital generalized lipodystrophy**

Congenital generalized lipodystrophy (CGL) requires multidisciplinary management and should be adjusted according to the specific features of the patients and the severity of the dystrophy. It may involve psychological support, aesthetic surgery, and high carbohydrate and a low-fat diet. Exercise should be tailored according to the type, with regular exercise for type 1 CGL and avoidance of strenuous exercise for type 4. Patients with type 4 may require β-adrenergic blockers or other antiarrhythmic medications. Patients with type 2 CGL and cardiomyopathy should be assessed individually to ensure their fitness for exercise and avoid when needed[208]. The presence of severe hypertriglyceridemia in CGL could benefit from fibrate drugs. Low-dose statins could help to reduce non-HDL cholesterol. If the patients develop DM, Metformin and sulphonylureas are the first lines of therapy. Insulin is usually needed in very high doses[209]. Leptin levels are markedly decreased in patients with generalized lipodystrophy. Leptin analogs as metreleptin can improve metabolic profile in CGL type 1 and type 2. Metreleptin centrally reduces the appetite through its effects on the hypothalamus. Metreleptin has been Food and Drug Administration-approved since 2014 to treat congenital and acquired generalized lipodystrophy with significant improvement of the quality of life and physiological well-being[210].

**Leprechaunism (Donohue syndrome)**

Recombinant IGF-1 is the only treatment available to treat patients with leprechaunism so far through preventing compensatory hyperinsulinemia[211]. IGF-1 has a similar structure to insulin and can reduce blood glucose by 6% of the effect of insulin. It can attach to insulin receptors, enhance peripheral glucose uptake, induce glycogen synthesis, and decrease protein catabolism. The effectiveness of therapy with Recombinant IGF-1 is debatable, and we need further studies. However, evidence from the currently available small number of *in vivo* studies seems promising[212].

**Hypertension in Children with IR and Obesity**

The presence of hypertension in patients with MS and IR increases the risk of cardiovascular disease and premature death. Angiotensin-converting enzyme inhibitors positively affect hypertriglyceridemia and IR and are considered the first-line drugs in treating hypertension in children with obesity with additional renal and cardiovascular protective benefits[213,214]. However, we need more randomized, controlled, double-blind, and long-term studies for a definitive conclusion.

**Fatty liver disease**

There is no specific pharmacologic treatment for fatty liver disease. The patients should start a low-fat diet and change their lifestyle to a more active style, and be encouraged to exercise. Triglyceride-lowering drugs and antioxidants can also be used. Insulin sensitizers, such as metformin, showed efficacy in animal and human studies[215].

**CONCLUSION**

As obesity increases in children, IR becomes more prevalent in children and adolescents than before. There is a broad range of genetic and acquired causes of IR. Early recognition of IR in the Pediatric age could prevent many possible short and long-term complications. Both prevention and management of IR resistance in children depend on changing the lifestyle, dietary intervention, and physical modification. Pharmacotherapy is indicated in selected cases. Surgery could help manage specific cases of IR and should be chosen meticulously.

**ACKNOWLEDGEMENTS**

We thank the anonymous referees for their valuable suggestions.

**REFERENCES**

1 **Cho J**, Hong H, Park S, Kim S, Kang H. Insulin Resistance and Its Association with Metabolic Syndrome in Korean Children. *Biomed Res Int* 2017; **2017**: 8728017 [PMID: 29457038 DOI: 10.1155/2017/8728017]

2 **Levy-Marchal C**, Arslanian S, Cutfield W, Sinaiko A, Druet C, Marcovecchio ML, Chiarelli F; ESPE-LWPES-ISPAD-APPES-APEG-SLEP-JSPE; Insulin Resistance in Children Consensus Conference Group. Insulin resistance in children: consensus, perspective, and future directions. *J Clin Endocrinol Metab* 2010; **95**: 5189-5198 [PMID: 20829185 DOI: 10.1210/jc.2010-1047]

3 **Fu Z**, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes. *Curr Diabetes Rev* 2013; **9**: 25-53 [PMID: 22974359]

4 **Reaven GM**. The insulin resistance syndrome: definition and dietary approaches to treatment. *Annu Rev Nutr* 2005; **25**: 391-406 [PMID: 16011472 DOI: 10.1146/annurev.nutr.24.012003.132155]

5 **Robinson TN**, Banda JA, Hale L, Lu AS, Fleming-Milici F, Calvert SL, Wartella E. Screen Media Exposure and Obesity in Children and Adolescents. *Pediatrics* 2017; **140**: S97-S101 [PMID: 29093041 DOI: 10.1542/peds.2016-1758K]

6 **Barker DJ**. The developmental origins of insulin resistance. *Horm Res* 2005; **64 Suppl 3**: 2-7 [PMID: 16439838 DOI: 10.1159/000089311]

7 **van der Aa MP**, Fazeli Farsani S, Knibbe CA, de Boer A, van der Vorst MM. Population-Based Studies on the Epidemiology of Insulin Resistance in Children. *J Diabetes Res* 2015; **2015**: 362375 [PMID: 26273668 DOI: 10.1155/2015/362375]

8 **Jurkovičová J**, Hirošová K, Vondrová D, Samohýl M, Štefániková Z, Filová A, Kachútová I, Babjaková J, Argalášová Ľ. The Prevalence of Insulin Resistance and the Associated Risk Factors in a Sample of 14-18-Year-Old Slovak Adolescents. *Int J Environ Res Public Health* 2021; **18** [PMID: 33494341 DOI: 10.3390/ijerph18030909]

9 **Das RR**, Mangaraj M, Nayak S, Satapathy AK, Mahapatro S, Goyal JP. Prevalence of Insulin Resistance in Urban Indian School Children Who Are Overweight/Obese: A Cross-Sectional Study. *Front Med (Lausanne)* 2021; **8**: 613594 [PMID: 33644095 DOI: 10.3389/fmed.2021.613594]

10 **Arslanian S**, Kim JY, Nasr A, Bacha F, Tfayli H, Lee S, Toledo FGS. Insulin sensitivity across the lifespan from obese adolescents to obese adults with impaired glucose tolerance: Who is worse off? *Pediatr Diabetes* 2018; **19**: 205-211 [PMID: 28726334 DOI: 10.1111/pedi.12562]

11 **Raygor V**, Abbasi F, Lazzeroni LC, Kim S, Ingelsson E, Reaven GM, Knowles JW. Impact of race/ethnicity on insulin resistance and hypertriglyceridaemia. *Diab Vasc Dis Res* 2019; **16**: 153-159 [PMID: 31014093 DOI: 10.1177/1479164118813890]

12 **Ehtisham S**, Crabtree N, Clark P, Shaw N, Barrett T. Ethnic differences in insulin resistance and body composition in United Kingdom adolescents. *J Clin Endocrinol Metab* 2005; **90**: 3963-3969 [PMID: 15840754 DOI: 10.1210/jc.2004-2001]

13 **Wilcox G**. Insulin and insulin resistance. *Clin Biochem Rev* 2005; **26**: 19-39 [PMID: 16278749]

14 **Kahn CR**. The molecular mechanism of insulin action. *Annu Rev Med* 1985; **36**: 429-451 [PMID: 2986528 DOI: 10.1146/annurev.me.36.020185.002241]

15 **Huang-Doran I**, Tomlinson P, Payne F, Gast A, Sleigh A, Bottomley W, Harris J, Daly A, Rocha N, Rudge S, Clark J, Kwok A, Romeo S, McCann E, Müksch B, Dattani M, Zucchini S, Wakelam M, Foukas LC, Savage DB, Murphy R, O'Rahilly S, Barroso I, Semple RK. Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations. *JCI Insight* 2016; **1**: e88766 [PMID: 27766312 DOI: 10.1172/jci.insight.88766]

16 **Buchanan TA**, Watanabe RM, Xiang AH. Limitations in surrogate measures of insulin resistance. *J Clin Endocrinol Metab* 2010; **95**: 4874-4876 [PMID: 21051585 DOI: 10.1210/jc.2010-2167]

17 **Ten S**, Maclaren N. Insulin resistance syndrome in children. *J Clin Endocrinol Metab* 2004; **89**: 2526-2539 [PMID: 15181020 DOI: 10.1210/jc.2004-0276]

18 **Farooqi IS**, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, Jebb SA, Lip GY, O'Rahilly S. Partial leptin deficiency and human adiposity. *Nature* 2001; **414**: 34-35 [PMID: 11689931 DOI: 10.1038/35102112]

19 **Croft JB**, Morrell D, Chase CL, Swift M. Obesity in heterozygous carriers of the gene for the Bardet-Biedl syndrome. *Am J Med Genet* 1995; **55**: 12-15 [PMID: 7702084 DOI: 10.1002/ajmg.1320550105]

20 **Verdecchia F**, Akcan N, Dastamani A, Morgan K, Semple RK, Shah P. Unusual Glycemic Presentations in a Child with a Novel Heterozygous Intragenic INSR Deletion. *Horm Res Paediatr* 2020; **93**: 396-401 [PMID: 33040071 DOI: 10.1159/000510462]

21 **Slavin BR**, Sarhane KA, von Guionneau N, Hanwright PJ, Qiu C, Mao HQ, Höke A, Tuffaha SH. Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury. *Front Bioeng Biotechnol* 2021; **9**: 695850 [PMID: 34249891 DOI: 10.3389/fbioe.2021.695850]

22 **Kuang J**, Zhang L, Xu Y, Xue J, Liang S, Xiao J. Reduced Insulin-Like Growth Factor 1 Is Associated with Insulin Resistance in Obese Prepubertal Boys. *Biomed Res Int* 2021; **2021**: 6680316 [PMID: 34485526 DOI: 10.1155/2021/6680316]

23 **Tyagi S**, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. *J Adv Pharm Technol Res* 2011; **2**: 236-240 [PMID: 22247890 DOI: 10.4103/2231-4040.90879]

24 **Kodo K**, Sugimoto S, Nakajima H, Mori J, Itoh I, Fukuhara S, Shigehara K, Nishikawa T, Kosaka K, Hosoi H. Erythropoietin (EPO) ameliorates obesity and glucose homeostasis by promoting thermogenesis and endocrine function of classical brown adipose tissue (BAT) in diet-induced obese mice. *PLoS One* 2017; **12**: e0173661 [PMID: 28288167 DOI: 10.1371/journal.pone.0173661]

25 **Goran MI**, Gower BA. Longitudinal study on pubertal insulin resistance. *Diabetes* 2001; **50**: 2444-2450 [PMID: 11679420 DOI: 10.2337/diabetes.50.11.2444]

26 **Martins LM**, Fernandes VO, Carvalho MMD, Gadelha DD, Queiroz PC, Montenegro Junior RM. Type B insulin resistance syndrome: a systematic review. *Arch Endocrinol Metab* 2020; **64**: 337-348 [PMID: 32813762 DOI: 10.20945/2359-3997000000257]

27 **van Raalte DH**, Brands M, van der Zijl NJ, Muskiet MH, Pouwels PJ, Ackermans MT, Sauerwein HP, Serlie MJ, Diamant M. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. *Diabetologia* 2011; **54**: 2103-2112 [PMID: 21562755 DOI: 10.1007/s00125-011-2174-9]

28 **Baudrand R**, Campino C, Carvajal CA, Olivieri O, Guidi G, Faccini G, Vöhringer PA, Cerda J, Owen G, Kalergis AM, Fardella CE. High sodium intake is associated with increased glucocorticoid production, insulin resistance and metabolic syndrome. *Clin Endocrinol (Oxf)* 2014; **80**: 677-684 [PMID: 23594269 DOI: 10.1111/cen.12225]

29 **De Wit S**, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte Ad, Fontas E, Law MG, Friis-Møller N, Phillips A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *Diabetes Care* 2008; **31**: 1224-1229 [PMID: 18268071 DOI: 10.2337/dc07-2013]

30 **Greenfield JR**, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, O'Rahilly S. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. *Diabet Med* 2009; **26**: 79-82 [PMID: 19125765 DOI: 10.1111/j.1464-5491.2008.02621.x]

31 **Coles N**, Patel BP, Birken C, Hanley AJ, Retnakaran R, K Hamilton J. Determinants of insulin resistance in children exposed to gestational diabetes in utero. *Pediatr Diabetes* 2020; **21**: 1150-1158 [PMID: 32808724 DOI: 10.1111/pedi.13104]

32 **Hillier TA**, Pedula KL, Schmidt MM, Mullen JA, Charles MA, Pettitt DJ. Childhood obesity and metabolic imprinting: the ongoing effects of maternal hyperglycemia. *Diabetes Care* 2007; **30**: 2287-2292 [PMID: 17519427 DOI: 10.2337/dc06-2361]

33 **Sobngwi E**, Boudou P, Mauvais-Jarvis F, Leblanc H, Velho G, Vexiau P, Porcher R, Hadjadj S, Pratley R, Tataranni PA, Calvo F, Gautier JF. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. *Lancet* 2003; **361**: 1861-1865 [PMID: 12788573 DOI: 10.1016/S0140-6736(03)13505-2]

34 **Huang R**, Dong Y, Nuyt AM, Levy E, Wei SQ, Julien P, Fraser WD, Luo ZC. Large birth size, infancy growth pattern, insulin resistance and β-cell function. *Eur J Endocrinol* 2021; **185**: 77-85 [PMID: 33914700 DOI: 10.1530/EJE-20-1332]

35 **Wilkin TJ**, Metcalf BS, Murphy MJ, Kirkby J, Jeffery AN, Voss LD. The relative contributions of birth weight, weight change, and current weight to insulin resistance in contemporary 5-year-olds: the EarlyBird Study. *Diabetes* 2002; **51**: 3468-3472 [PMID: 12453901 DOI: 10.2337/diabetes.51.12.3468]

36 **Efstathiou SP**, Skeva II, Zorbala E, Georgiou E, Mountokalakis TD. Metabolic syndrome in adolescence: can it be predicted from natal and parental profile? The Prediction of Metabolic Syndrome in Adolescence (PREMA) study. *Circulation* 2012; **125**: 902-910 [PMID: 22247492 DOI: 10.1161/CIRCULATIONAHA.111.034546]

37 **Ibáñez L**, Lopez-Bermejo A, Suárez L, Marcos MV, Díaz M, de Zegher F. Visceral adiposity without overweight in children born small for gestational age. *J Clin Endocrinol Metab* 2008; **93**: 2079-2083 [PMID: 18334595 DOI: 10.1210/jc.2007-2850]

38 **Liu C**, Wu B, Lin N, Fang X. Insulin resistance and its association with catch-up growth in Chinese children born small for gestational age. *Obesity (Silver Spring)* 2017; **25**: 172-177 [PMID: 27865057 DOI: 10.1002/oby.21683]

39 **Dabelea D**, Pettitt DJ, Hanson RL, Imperatore G, Bennett PH, Knowler WC. Birth weight, type 2 diabetes, and insulin resistance in Pima Indian children and young adults. *Diabetes Care* 1999; **22**: 944-950 [PMID: 10372247 DOI: 10.2337/diacare.22.6.944]

40 **Murtaugh MA**, Jacobs DR Jr, Moran A, Steinberger J, Sinaiko AR. Relation of birth weight to fasting insulin, insulin resistance, and body size in adolescence. *Diabetes Care* 2003; **26**: 187-192 [PMID: 12502679 DOI: 10.2337/diacare.26.1.187]

41 **Hofman PL**, Regan F, Jackson WE, Jefferies C, Knight DB, Robinson EM, Cutfield WS. Premature birth and later insulin resistance. *N Engl J Med* 2004; **351**: 2179-2186 [PMID: 15548778 DOI: 10.1056/NEJMoa042275]

42 **do Vale Moreira NC**, Ceriello A, Basit A, Balde N, Mohan V, Gupta R, Misra A, Bhowmik B, Lee MK, Zuo H, Shi Z, Wang Y, Montenegro RM, Fernandes VO, Colagiuri S, Boulton AJM, Hussain A. Race/ethnicity and challenges for optimal insulin therapy. *Diabetes Res Clin Pract* 2021; **175**: 108823 [PMID: 33887353 DOI: 10.1016/j.diabres.2021.108823]

43 **Kelsey MM**, Zeitler PS. Insulin Resistance of Puberty. *Curr Diab Rep* 2016; **16**: 64 [PMID: 27179965 DOI: 10.1007/s11892-016-0751-5]

44 **Ruiz-Ojeda FJ**, Anguita-Ruiz A, Leis R, Aguilera CM. Genetic Factors and Molecular Mechanisms of Vitamin D and Obesity Relationship. *Ann Nutr Metab* 2018; **73**: 89-99 [PMID: 29982250 DOI: 10.1159/000490669]

45 **Abbas MA**. Physiological functions of Vitamin D in adipose tissue. *J Steroid Biochem Mol Biol* 2017; **165**: 369-381 [PMID: 27520301 DOI: 10.1016/j.jsbmb.2016.08.004]

46 **Pires LV**, González-Gil EM, Anguita-Ruiz A, Bueno G, Gil-Campos M, Vázquez-Cobela R, Pérez-Ferreirós A, Moreno LA, Gil Á, Leis R, Aguilera CM. The Vitamin D Decrease in Children with Obesity Is Associated with the Development of Insulin Resistance during Puberty: The PUBMEP Study. *Nutrients* 2021; **13** [PMID: 34960039 DOI: 10.3390/nu13124488]

47 **Bacha F**, Saad R, Gungor N, Arslanian SA. Are obesity-related metabolic risk factors modulated by the degree of insulin resistance in adolescents? *Diabetes Care* 2006; **29**: 1599-1604 [PMID: 16801585 DOI: 10.2337/dc06-0581]

48 **Preis SR**, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, Meigs JB, Sutherland P, D'Agostino RB Sr, O'Donnell CJ, Fox CS. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. *Obesity (Silver Spring)* 2010; **18**: 2191-2198 [PMID: 20339361 DOI: 10.1038/oby.2010.59]

49 **Do TTH**, Marie G, Héloïse D, Guillaume D, Marthe M, Bruno F, Marion B. Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration. *J Steroid Biochem Mol Biol* 2019; **185**: 150-162 [PMID: 30145227 DOI: 10.1016/j.jsbmb.2018.08.010]

50 **Weiss R**, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R, Shulman GI, Caprio S. Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. *Lancet* 2003; **362**: 951-957 [PMID: 14511928 DOI: 10.1016/S0140-6736(03)14364-4]

51 **de Mutsert R**, Gast K, Widya R, de Koning E, Jazet I, Lamb H, le Cessie S, de Roos A, Smit J, Rosendaal F, den Heijer M. Associations of Abdominal Subcutaneous and Visceral Fat with Insulin Resistance and Secretion Differ Between Men and Women: The Netherlands Epidemiology of Obesity Study. *Metab Syndr Relat Disord* 2018; **16**: 54-63 [PMID: 29338526 DOI: 10.1089/met.2017.0128]

52 **Weigensberg MJ**, Ball GD, Shaibi GQ, Cruz ML, Gower BA, Goran MI. Dietary fat intake and insulin resistance in black and white children. *Obes Res* 2005; **13**: 1630-1637 [PMID: 16222067 DOI: 10.1038/oby.2005.200]

53 **Marson EC**, Delevatti RS, Prado AK, Netto N, Kruel LF. Effects of aerobic, resistance, and combined exercise training on insulin resistance markers in overweight or obese children and adolescents: A systematic review and meta-analysis. *Prev Med* 2016; **93**: 211-218 [PMID: 27773709 DOI: 10.1016/j.ypmed.2016.10.020]

54 **Bardsley MZ**, Falkner B, Kowal K, Ross JL. Insulin resistance and metabolic syndrome in prepubertal boys with Klinefelter syndrome. *Acta Paediatr* 2011; **100**: 866-870 [PMID: 21251059 DOI: 10.1111/j.1651-2227.2011.02161.x]

55 **Forno E**, Han YY, Muzumdar RH, Celedón JC. Insulin resistance, metabolic syndrome, and lung function in US adolescents with and without asthma. *J Allergy Clin Immunol* 2015; **136**: 304-11.e8 [PMID: 25748066 DOI: 10.1016/j.jaci.2015.01.010]

56 **Hakim F**, Kheirandish-Gozal L, Gozal D. Obesity and Altered Sleep: A Pathway to Metabolic Derangements in Children? *Semin Pediatr Neurol* 2015; **22**: 77-85 [PMID: 26072337 DOI: 10.1016/j.spen.2015.04.006]

57 **Geer EB**, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. *Endocrinol Metab Clin North Am* 2014; **43**: 75-102 [PMID: 24582093 DOI: 10.1016/j.ecl.2013.10.005]

58 **De Hert M**, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol* 2011; **8**: 114-126 [PMID: 22009159 DOI: 10.1038/nrendo.2011.156]

59 **Scalarone GM**, Legendre AM, Clark KA, Pusater K. Evaluation of a commercial DNA probe assay for the identification of clinical isolates of Blastomyces dermatitidis from dogs. *J Med Vet Mycol* 1992; **30**: 43-49 [PMID: 1573520 DOI: 10.1080/02681219280000061]

60 **Goldfine AB**, Bouche C, Parker RA, Kim C, Kerivan A, Soeldner JS, Martin BC, Warram JH, Kahn CR. Insulin resistance is a poor predictor of type 2 diabetes in individuals with no family history of disease. *Proc Natl Acad Sci U S A* 2003; **100**: 2724-2729 [PMID: 12591951 DOI: 10.1073/pnas.0438009100]

61 **Cali AM**, Man CD, Cobelli C, Dziura J, Seyal A, Shaw M, Allen K, Chen S, Caprio S. Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. *Diabetes Care* 2009; **32**: 456-461 [PMID: 19106382 DOI: 10.2337/dc08-1274]

62 **Ahuja V**, Kadowaki T, Evans RW, Kadota A, Okamura T, El Khoudary SR, Fujiyoshi A, Barinas-Mitchell EJ, Hisamatsu T, Vishnu A, Miura K, Maegawa H, El-Saed A, Kashiwagi A, Kuller LH, Ueshima H, Sekikawa A; ERA JUMP Study Group. Comparison of HOMA-IR, HOMA-β% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study. *Diabetologia* 2015; **58**: 265-271 [PMID: 25316435 DOI: 10.1007/s00125-014-3414-6]

63 **Lee S**, Gungor N, Bacha F, Arslanian S. Insulin resistance: link to the components of the metabolic syndrome and biomarkers of endothelial dysfunction in youth. *Diabetes Care* 2007; **30**: 2091-2097 [PMID: 17475936 DOI: 10.2337/dc07-0203]

64 **Calle EE**, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 2003; **348**: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]

65 **Lin X**, Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. *Front Endocrinol (Lausanne)* 2021; **12**: 706978 [PMID: 34552557 DOI: 10.3389/fendo.2021.706978]

66 **Kahn SE**, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006; **444**: 840-846 [PMID: 17167471 DOI: 10.1038/nature05482]

67 **Erion KA**, Corkey BE. Hyperinsulinemia: a Cause of Obesity? *Curr Obes Rep* 2017; **6**: 178-186 [PMID: 28466412 DOI: 10.1007/s13679-017-0261-z]

68 **Genuth SM**, Bennett PH, Miller M, Burch TA. Hyperinsulinism in obese diabetic Pima Indians. *Metabolism* 1967; **16**: 1010-1015 [PMID: 6060283 DOI: 10.1016/0026-0495(67)90094-7]

69 **Chen YY**, Wang JP, Jiang YY, Li H, Hu YH, Lee KO, Li GW. Fasting Plasma Insulin at 5 Years of Age Predicted Subsequent Weight Increase in Early Childhood over a 5-Year Period-The Da Qing Children Cohort Study. *PLoS One* 2015; **10**: e0127389 [PMID: 26047327 DOI: 10.1371/journal.pone.0127389]

70 **Arslanian SA**, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in african-american children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. *Diabetes* 2002; **51**: 3014-3019 [PMID: 12351441 DOI: 10.2337/diabetes.51.10.3014]

71 **Cases JA**, Barzilai N. The regulation of body fat distribution and the modulation of insulin action. *Int J Obes Relat Metab Disord* 2000; **24 Suppl 4**: S63-S66 [PMID: 11126245 DOI: 10.1038/sj.ijo.0801508]

72 **Tomlinson JW**, Stewart PM. The functional consequences of 11beta-hydroxysteroid dehydrogenase expression in adipose tissue. *Horm Metab Res* 2002; **34**: 746-751 [PMID: 12660893 DOI: 10.1055/s-2002-38242]

73 **Montague CT**, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. *Diabetes* 2000; **49**: 883-888 [PMID: 10866038 DOI: 10.2337/diabetes.49.6.883]

74 **Ikezaki H**, Ai M, Schaefer EJ, Otokozawa S, Asztalos BF, Nakajima K, Zhou Y, Liu CT, Jacques PF, Cupples LA, Furusyo N. Cardiovascular disease prevalence and insulin resistance in the Kyushu-Okinawa Population Study and the Framingham Offspring Study. *J Clin Lipidol* 2017; **11**: 348-356 [PMID: 28502490 DOI: 10.1016/j.jacl.2017.01.014]

75 **Steinberger J**, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young); American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). *Circulation* 2003; **107**: 1448-1453 [PMID: 12642369 DOI: 10.1161/01.cir.0000060923.07573.f2]

76 **Stout RW**, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. *Circ Res* 1975; **36**: 319-327 [PMID: 163709 DOI: 10.1161/01.res.36.2.319]

77 **Mudau M**, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. *Cardiovasc J Afr* 2012; **23**: 222-231 [PMID: 22614668 DOI: 10.5830/CVJA-2011-068]

78 **Davis PH**, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. *Circulation* 2001; **104**: 2815-2819 [PMID: 11733400 DOI: 10.1161/hc4601.099486]

79 **Berenson GS**. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease. The Bogalusa Heart Study. *Am J Cardiol* 2002; **90**: 3L-7L [PMID: 12459418 DOI: 10.1016/s0002-9149(02)02953-3]

80 **Schwimmer JB**, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; **118**: 1388-1393 [PMID: 17015527 DOI: 10.1542/peds.2006-1212]

81 **Peng L**, Wu S, Zhou N, Zhu S, Liu Q, Li X. Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. *BMC Pediatr* 2021; **21**: 122 [PMID: 33711964 DOI: 10.1186/s12887-021-02595-2]

82 **Hadizadeh F**, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. *World J Gastrointest Pathophysiol* 2017; **8**: 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11]

83 **Nováková B**, Brůha R. Serum markers in diagnostics of steatohepatitis. *Vnitr Lek* 2019; **65**: 577-582 [PMID: 31635469]

84 **Fernandez-Real JM**, Pugeat M, López-Bermejo A, Bornet H, Ricart W. Corticosteroid-binding globulin affects the relationship between circulating adiponectin and cortisol in men and women. *Metabolism* 2005; **54**: 584-589 [PMID: 15877287 DOI: 10.1016/j.metabol.2004.11.015]

85 **Moradi L**, Amiri F, Shahbazian H. Insulin resistance and pseudoacromegaly: A case report. *Diabetes Metab Syndr* 2019; **13**: 901-903 [PMID: 31336543 DOI: 10.1016/j.dsx.2018.12.009]

86 **Rajpathak SN**, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE, Strickler HD. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. *Diabetes Metab Res Rev* 2009; **25**: 3-12 [PMID: 19145587 DOI: 10.1002/dmrr.919]

87 **Llamas-Covarrubias IM**, Llamas-Covarrubias MA, Martinez-López E, Zepeda-Carrillo EA, Rivera-León EA, Palmeros-Sánchez B, Alcalá-Zermeño JL, Sánchez-Enríquez S. Association of A-604G ghrelin gene polymorphism and serum ghrelin levels with the risk of obesity in a mexican population. *Mol Biol Rep* 2017; **44**: 289-293 [PMID: 28597412 DOI: 10.1007/s11033-017-4109-0]

88 **Gierach M**, Gierach J, Junik R. Insulin resistance and thyroid disorders. *Endokrynol Pol* 2014; **65**: 70-76 [PMID: 24549605 DOI: 10.5603/EP.2014.0010]

89 **Sørensen K**, Aksglaede L, Munch-Andersen T, Aachmann-Andersen NJ, Petersen JH, Hilsted L, Helge JW, Juul A. Sex hormone-binding globulin levels predict insulin sensitivity, disposition index, and cardiovascular risk during puberty. *Diabetes Care* 2009; **32**: 909-914 [PMID: 19196890 DOI: 10.2337/dc08-1618]

90 **Chen F**, Liao Y, Chen M, Yin H, Chen G, Huang Q, Chen L, Yang X, Zhang W, Wang P, Yin G. Evaluation of the Efficacy of Sex Hormone-Binding Globulin in Insulin Resistance Assessment Based on HOMA-IR in Patients with PCOS. *Reprod Sci* 2021; **28**: 2504-2513 [PMID: 33721297 DOI: 10.1007/s43032-021-00535-0]

91 **Qu X**, Donnelly R. Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome. *Int J Mol Sci* 2020; **21** [PMID: 33139661 DOI: 10.3390/ijms21218191]

92 **Veldhuis JD**, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY. Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women. *Am J Physiol Endocrinol Metab* 2009; **297**: E367-E374 [PMID: 19470834 DOI: 10.1152/ajpendo.00230.2009]

93 **Littlejohn EE**, Weiss RE, Deplewski D, Edidin DV, Rosenfield R. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. *J Pediatr Endocrinol Metab* 2007; **20**: 41-51 [PMID: 17315528 DOI: 10.1515/jpem.2007.20.1.41]

94 **Walsh JS**, Bowles S, Evans AL. Vitamin D in obesity. *Curr Opin Endocrinol Diabetes Obes* 2017; **24**: 389-394 [PMID: 28915134 DOI: 10.1097/MED.0000000000000371]

95 **Lind L**, Hänni A, Lithell H, Hvarfner A, Sörensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. *Am J Hypertens* 1995; **8**: 894-901 [PMID: 8541004 DOI: 10.1016/0895-7061(95)00154-H]

96 **Ashraf AP**, Huisingh C, Alvarez JA, Wang X, Gower BA. Insulin resistance indices are inversely associated with vitamin D binding protein concentrations. *J Clin Endocrinol Metab* 2014; **99**: 178-183 [PMID: 24170105 DOI: 10.1210/jc.2013-2452]

97 **Sergeev IN**. Vitamin D-mediated apoptosis in cancer and obesity. *Horm Mol Biol Clin Investig* 2014; **20**: 43-49 [PMID: 25460294 DOI: 10.1515/hmbci-2014-0035]

98 **Pratley RE**, Thompson DB, Prochazka M, Baier L, Mott D, Ravussin E, Sakul H, Ehm MG, Burns DK, Foroud T, Garvey WT, Hanson RL, Knowler WC, Bennett PH, Bogardus C. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. *J Clin Invest* 1998; **101**: 1757-1764 [PMID: 9541507 DOI: 10.1172/JCI1850]

99 **Ford ES**, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. *J Pediatr* 2001; **138**: 486-492 [PMID: 11295710 DOI: 10.1067/mpd.2001.112898]

100 **Visser M**, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 1999; **282**: 2131-2135 [PMID: 10591334 DOI: 10.1001/jama.282.22.2131]

101 **DeBoer MD**. Assessing and Managing the Metabolic Syndrome in Children and Adolescents. *Nutrients* 2019; **11** [PMID: 31382417 DOI: 10.3390/nu11081788]

102 **Ford ES**, Mokdad AH, Liu S. Healthy Eating Index and C-reactive protein concentration: findings from the National Health and Nutrition Examination Survey III, 1988-1994. *Eur J Clin Nutr* 2005; **59**: 278-283 [PMID: 15494735 DOI: 10.1038/sj.ejcn.1602070]

103 **Sansone F**, Attanasi M, Di Pillo S, Chiarelli F. Asthma and Obesity in Children. *Biomedicines* 2020; **8** [PMID: 32708186 DOI: 10.3390/biomedicines8070231]

104 **Castro-Rodríguez JA**, Holberg CJ, Morgan WJ, Wright AL, Martinez FD. Increased incidence of asthmalike symptoms in girls who become overweight or obese during the school years. *Am J Respir Crit Care Med* 2001; **163**: 1344-1349 [PMID: 11371399 DOI: 10.1164/ajrccm.163.6.2006140]

105 **McLoughlin RF**, Berthon BS, Wood LG. Weight loss in obese children with asthma - is it important? *Paediatr Respir Rev* 2021; **37**: 10-14 [PMID: 32303450 DOI: 10.1016/j.prrv.2020.02.007]

106 **Siriwat R**, Wang L, Shah V, Mehra R, Ibrahim S. Obstructive sleep apnea and insulin resistance in children with obesity. *J Clin Sleep Med* 2020; **16**: 1081-1090 [PMID: 32118578 DOI: 10.5664/jcsm.8414]

107 **Nithun TM**, Ranugha PSS, Betkerur JB, Shastry V. Association of Acanthosis Nigricans and Insulin Resistance in Indian Children and Youth - A HOMA2-IR Based Cross-Sectional Study. *Indian Dermatol Online J* 2019; **10**: 272-278 [PMID: 31149570 DOI: 10.4103/idoj.IDOJ\_303\_18]

108 **Copeland K**, Pankratz K, Cathey V, Immohotichey P, Maddox J, Felton B, McIntosh R, Parker D, Burgin C, Blackett P. Acanthosis Nigricans, insulin resistance (HOMA) and dyslipidemia among Native American children. *J Okla State Med Assoc* 2006; **99**: 19-24 [PMID: 16499154]

109 **Brown B**, Noonan C, Bentley B, Conway K, Corcoran M, FourStar K, Gress S, Wagner S. Acanthosis nigricans among Northern Plains American Indian children. *J Sch Nurs* 2010; **26**: 450-460 [PMID: 20595701 DOI: 10.1177/1059840510376383]

110 **Özalp Kızılay D**, Yalın Sapmaz Ş, Şen S, Özkan Y, Ersoy B. Insulin Resistance as Related to Psychiatric Disorders in Obese Children. *J Clin Res Pediatr Endocrinol* 2018; **10**: 364-372 [PMID: 29789273 DOI: 10.4274/jcrpe.0055]

111 **Holder T**, Giannini C, Santoro N, Pierpont B, Shaw M, Duran E, Caprio S, Weiss R. A low disposition index in adolescent offspring of mothers with gestational diabetes: a risk marker for the development of impaired glucose tolerance in youth. *Diabetologia* 2014; **57**: 2413-2420 [PMID: 25168408 DOI: 10.1007/s00125-014-3345-2]

112 **Muhlhausler B**, Smith SR. Early-life origins of metabolic dysfunction: role of the adipocyte. *Trends Endocrinol Metab* 2009; **20**: 51-57 [PMID: 19095460 DOI: 10.1016/j.tem.2008.10.006]

113 **Baker JL**, Farpour-Lambert NJ, Nowicka P, Pietrobelli A, Weiss R; Childhood Obesity Task Force of the European Association for the Study of Obesity. Evaluation of the overweight/obese child--practical tips for the primary health care provider: recommendations from the Childhood Obesity Task Force of the European Association for the Study of Obesity. *Obes Facts* 2010; **3**: 131-137 [PMID: 20484947 DOI: 10.1159/000295112]

114 **Bhattacharya S**, Aggarwal P, Bera OP, Saleem SM, Shikha D, Vallabh V, Juyal R, Singh A. COVID-19 and childhood obesity (CO-BESITY) in the era of new normal life: A need for a policy research. *J Public Health Res* 2021; **10** [PMID: 34918498 DOI: 10.4081/jphr.2021.2673]

115 **Poitras VJ**, Gray CE, Borghese MM, Carson V, Chaput JP, Janssen I, Katzmarzyk PT, Pate RR, Connor Gorber S, Kho ME, Sampson M, Tremblay MS. Systematic review of the relationships between objectively measured physical activity and health indicators in school-aged children and youth. *Appl Physiol Nutr Metab* 2016; **41**: S197-S239 [PMID: 27306431 DOI: 10.1139/apnm-2015-0663]

116 **Greabu M**, Badoiu SC, Stanescu-Spinu II, Miricescu D, Totan AR, Badoiu SE, Costagliola M, Jinga V. Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review. *Int J Mol Sci* 2021; **22** [PMID: 34575946 DOI: 10.3390/ijms22189782]

117 **Ariaans G**, de Jong S, Gietema JA, Lefrandt JD, de Vries EG, Jalving M. Cancer-drug induced insulin resistance: innocent bystander or unusual suspect. *Cancer Treat Rev* 2015; **41**: 376-384 [PMID: 25724262 DOI: 10.1016/j.ctrv.2015.02.007]

118 **Zahedi S**, Jaffer R, Iyer A. A systematic review of screen-time literature to inform educational policy and practice during COVID-19. *Int J Educ Res Open* 2021; **2**: 100094 [PMID: 35059672 DOI: 10.1016/j.ijedro.2021.100094]

119 **Kim Y**, Park H. Does Regular Exercise without Weight Loss Reduce Insulin Resistance in Children and Adolescents? *Int J Endocrinol* 2013; **2013**: 402592 [PMID: 24454364 DOI: 10.1155/2013/402592]

120 **Arslanian S**, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. *Diabetes Care* 2018; **41**: 2648-2668 [PMID: 30425094 DOI: 10.2337/dci18-0052]

121 **Zhang Y**, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. *BMC Psychiatry* 2017; **17**: 373 [PMID: 29162032 DOI: 10.1186/s12888-017-1539-0]

122 **Rosner B**, Prineas R, Loggie J, Daniels SR. Percentiles for body mass index in U.S. children 5 to 17 years of age. *J Pediatr* 1998; **132**: 211-222 [PMID: 9506630 DOI: 10.1016/s0022-3476(98)70434-2]

123 **Ighbariya A**, Weiss R. Insulin Resistance, Prediabetes, Metabolic Syndrome: What Should Every Pediatrician Know? *J Clin Res Pediatr Endocrinol* 2017; **9**: 49-57 [PMID: 29280741 DOI: 10.4274/jcrpe.2017.S005]

124 **Yang HR**, Chang EJ. Insulin resistance, body composition, and fat distribution in obese children with nonalcoholic fatty liver disease. *Asia Pac J Clin Nutr* 2016; **25**: 126-133 [PMID: 26965771 DOI: 10.6133/apjcn.2016.25.1.15]

125 **Giordano U**, Della Corte C, Cafiero G, Liccardo D, Turchetta A, Hoshemand KM, Fintini D, Bedogni G, Matteucci MC, Nobili V. Association between nocturnal blood pressure dipping and insulin resistance in children affected by NAFLD. *Eur J Pediatr* 2014; **173**: 1511-1518 [PMID: 24934631 DOI: 10.1007/s00431-014-2342-2]

126 **Flanagan DE**, Vaile JC, Petley GW, Moore VM, Godsland IF, Cockington RA, Robinson JS, Phillips DI. The autonomic control of heart rate and insulin resistance in young adults. *J Clin Endocrinol Metab* 1999; **84**: 1263-1267 [PMID: 10199765 DOI: 10.1210/jcem.84.4.5592]

127 **Ren J**, Wu NN, Wang S, Sowers JR, Zhang Y. Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. *Physiol Rev* 2021; **101**: 1745-1807 [PMID: 33949876 DOI: 10.1152/physrev.00030.2020]

128 **Ardern CI**, Katzmarzyk PT, Janssen I, Ross R. Discrimination of health risk by combined body mass index and waist circumference. *Obes Res* 2003; **11**: 135-142 [PMID: 12529496 DOI: 10.1038/oby.2003.22]

129 **Zhu S**, Heshka S, Wang Z, Shen W, Allison DB, Ross R, Heymsfield SB. Combination of BMI and Waist Circumference for Identifying Cardiovascular Risk Factors in Whites. *Obes Res* 2004; **12**: 633-645 [PMID: 15090631 DOI: 10.1038/oby.2004.73]

130 **Ziolkowska S**, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. *Int J Mol Sci* 2021; **22** [PMID: 34681787 DOI: 10.3390/ijms222011128]

131 **Ibáñez L**, Potau N, Zampolli M, Riqué S, Saenger P, Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. *J Clin Endocrinol Metab* 1997; **82**: 2283-2288 [PMID: 9215308 DOI: 10.1210/jcem.82.7.4084]

132 **Liu X**, Tang HY, Luo ZC. [Insulin Resistance and Skin Diseases]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2020; **42**: 247-250 [PMID: 32385033 DOI: 10.3881/j.issn.1000-503X.11609]

133 **Calcaterra V**, De Silvestri A, Schneider L, Acunzo M, Vittoni V, Meraviglia G, Bergamaschi F, Zuccotti G, Mameli C. Acanthosis Nigricans in Children and Adolescents with Type 1 Diabetes or Obesity: The Potential Interplay Role between Insulin Resistance and Excess Weight. *Children (Basel)* 2021; **8** [PMID: 34438601 DOI: 10.3390/children8080710]

134 **Sudy E**, Urbina F, Maliqueo M, Sir T. Screening of glucose/insulin metabolic alterations in men with multiple skin tags on the neck. *J Dtsch Dermatol Ges* 2008; **6**: 852-855, 852-856 [PMID: 18397315 DOI: 10.1111/j.1610-0387.2008.06720.x]

135 **Brzeziński M**, Czubek Z, Niedzielska A, Jankowski M, Kobus T, Ossowski Z. Relationship between lower-extremity defects and body mass among polish children: a cross-sectional study. *BMC Musculoskelet Disord* 2019; **20**: 84 [PMID: 30777046 DOI: 10.1186/s12891-019-2460-0]

136 **Katz A**, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000; **85**: 2402-2410 [PMID: 10902785 DOI: 10.1210/jcem.85.7.6661]

137 **Kim JK**. Hyperinsulinemic-euglycemic clamp to assess insulin sensitivity in vivo. *Methods Mol Biol* 2009; **560**: 221-238 [PMID: 19504253 DOI: 10.1007/978-1-59745-448-3\_15]

138 **Knowles JW**, Assimes TL, Tsao PS, Natali A, Mari A, Quertermous T, Reaven GM, Abbasi F. Measurement of insulin-mediated glucose uptake: direct comparison of the modified insulin suppression test and the euglycemic, hyperinsulinemic clamp. *Metabolism* 2013; **62**: 548-553 [PMID: 23151437 DOI: 10.1016/j.metabol.2012.10.002]

139 **Muniyappa R**, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. *Am J Physiol Endocrinol Metab* 2008; **294**: E15-E26 [PMID: 17957034 DOI: 10.1152/ajpendo.00645.2007]

140 **Tompkins CL**, Cefalu W, Ravussin E, Goran M, Soros A, Volaufova J, Vargas A, Sothern MS. Feasibility of intravenous glucose tolerance testing prior to puberty. *Int J Pediatr Obes* 2010; **5**: 51-55 [PMID: 19579147 DOI: 10.3109/17477160903055937]

141 **O'Donovan SD**, Lenz M, Goossens GH, van der Kallen CJH, Eussen SJMP, Stehouwer CDA, van Greevenbroek MM, Schram MT, Sep SJ, Peeters RLM, Blaak EE, van Riel NAW, de Kok TMCM, Arts ICW. Improved quantification of muscle insulin sensitivity using oral glucose tolerance test data: the MISI Calculator. *Sci Rep* 2019; **9**: 9388 [PMID: 31253846 DOI: 10.1038/s41598-019-45858-w]

142 **Yeckel CW**, Weiss R, Dziura J, Taksali SE, Dufour S, Burgert TS, Tamborlane WV, Caprio S. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. *J Clin Endocrinol Metab* 2004; **89**: 1096-1101 [PMID: 15001593 DOI: 10.1210/jc.2003-031503]

143 **Singh B**, Saxena A. Surrogate markers of insulin resistance: A review. *World J Diabetes* 2010; **1**: 36-47 [PMID: 21537426 DOI: 10.4239/wjd.v1.i2.36]

144 **Fox C**, Bernardino L, Cochran J, Essig M, Bridges KG. Inappropriate Use of Homeostasis Model Assessment Cutoff Values for Diagnosing Insulin Resistance in Pediatric Studies. *J Am Osteopath Assoc* 2017; **117**: 689-696 [PMID: 29084322 DOI: 10.7556/jaoa.2017.135]

145 **Chen H**, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. *Diabetes* 2005; **54**: 1914-1925 [PMID: 15983190 DOI: 10.2337/diabetes.54.7.1914]

146 **Gutt M**, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB. Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. *Diabetes Res Clin Pract* 2000; **47**: 177-184 [PMID: 10741566 DOI: 10.1016/s0168-8227(99)00116-3]

147 **Zhang K**, Pan H, Wang L, Yang H, Zhu H, Gong F. Adipose Tissue Insulin Resistance is Closely Associated with Metabolic Syndrome in Northern Chinese Populations. *Diabetes Metab Syndr Obes* 2021; **14**: 1117-1128 [PMID: 33737823 DOI: 10.2147/DMSO.S291350]

148 **Neves FS**, Alvim RO, Zaniqueli D, Pani VO, Martins CR, Peçanha MAS, Barbosa MCR, Faria ER, Mill JG. TRI-PONDERAL MASS INDEX IS USEFUL FOR SCREENING CHILDREN AND ADOLESCENTS WITH INSULIN RESISTANCE. *Rev Paul Pediatr* 2020; **38**: e2019066 [PMID: 32187302 DOI: 10.1590/1984-0462/2020/38/2019066]

149 **US Preventive Services Task Force**, Grossman DC, Bibbins-Domingo K, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. *JAMA* 2017; **317**: 2417-2426 [PMID: 28632874 DOI: 10.1001/jama.2017.6803]

150 **Rutter MK**, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. *Diabetes* 2005; **54**: 3252-3257 [PMID: 16249452 DOI: 10.2337/diabetes.54.11.3252]

151 **Hui LL**, Kwok MK, Nelson EAS, Lee SL, Leung GM, Schooling CM. The association of breastfeeding with insulin resistance at 17 years: Prospective observations from Hong Kong's "Children of 1997" birth cohort. *Matern Child Nutr* 2018; **14** [PMID: 28776916 DOI: 10.1111/mcn.12490]

152 **Serrano NC**, Robles Silva A, Suárez DP, Gamboa-Delgado EM, Quintero-Lesmes DC. [Relationship between exclusive breastfeeding the first six months of life and development of insulin resistance in children and adolescents in Bucaramanga, Colombia]. *Nutr Hosp* 2018; **35**: 1042-1048 [PMID: 30307284 DOI: 10.20960/nh.1754]

153 **Jaafar R**, Tran S, Shah AN, Sun G, Valdearcos M, Marchetti P, Masini M, Swisa A, Giacometti S, Bernal-Mizrachi E, Matveyenko A, Hebrok M, Dor Y, Rutter GA, Koliwad SK, Bhushan A. mTORC1 to AMPK switching underlies β-cell metabolic plasticity during maturation and diabetes. *J Clin Invest* 2019; **129**: 4124-4137 [PMID: 31265435 DOI: 10.1172/JCI127021]

154 **van de Heijning BJM**, Oosting A, Kegler D, van der Beek EM. An Increased Dietary Supply of Medium-Chain Fatty Acids during Early Weaning in Rodents Prevents Excessive Fat Accumulation in Adulthood. *Nutrients* 2017; **9** [PMID: 28632178 DOI: 10.3390/nu9060631]

155 **Cerf ME**. High fat programming of beta cell compensation, exhaustion, death and dysfunction. *Pediatr Diabetes* 2015; **16**: 71-78 [PMID: 25682938 DOI: 10.1111/pedi.12137]

156 **Klancic T**, Laforest-Lapointe I, Wong J, Choo A, Nettleton JE, Chleilat F, Arrieta MC, Reimer RA. Concurrent Prebiotic Intake Reverses Insulin Resistance Induced by Early-Life Pulsed Antibiotic in Rats. *Biomedicines* 2021; **9** [PMID: 33445530 DOI: 10.3390/biomedicines9010066]

157 **Kaitosaari T**, Rönnemaa T, Viikari J, Raitakari O, Arffman M, Marniemi J, Kallio K, Pahkala K, Jokinen E, Simell O. Low-saturated fat dietary counseling starting in infancy improves insulin sensitivity in 9-year-old healthy children: the Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) study. *Diabetes Care* 2006; **29**: 781-785 [PMID: 16567815 DOI: 10.2337/diacare.29.04.06.dc05-1523]

158 **Van Hulst A**, Paradis G, Harnois-Leblanc S, Benedetti A, Drapeau V, Henderson M. Lowering Saturated Fat and Increasing Vegetable and Fruit Intake May Increase Insulin Sensitivity 2 Years Later in Children with a Family History of Obesity. *J Nutr* 2018; **148**: 1838-1844 [PMID: 30383280 DOI: 10.1093/jn/nxy189]

159 **Henderson M**, Gray-Donald K, Mathieu ME, Barnett TA, Hanley JA, O'Loughlin J, Tremblay A, Lambert M. How are physical activity, fitness, and sedentary behavior associated with insulin sensitivity in children? *Diabetes Care* 2012; **35**: 1272-1278 [PMID: 22492585 DOI: 10.2337/dc11-1785]

160 **Allen DB**, Nemeth BA, Clark RR, Peterson SE, Eickhoff J, Carrel AL. Fitness is a stronger predictor of fasting insulin levels than fatness in overweight male middle-school children. *J Pediatr* 2007; **150**: 383-387 [PMID: 17382115 DOI: 10.1016/j.jpeds.2006.12.051]

161 **Spartano NL**, Stevenson MD, Xanthakis V, Larson MG, Andersson C, Murabito JM, Vasan RS. Associations of objective physical activity with insulin sensitivity and circulating adipokine profile: the Framingham Heart Study. *Clin Obes* 2017; **7**: 59-69 [PMID: 28112860 DOI: 10.1111/cob.12177]

162 **Bell LM**, Watts K, Siafarikas A, Thompson A, Ratnam N, Bulsara M, Finn J, O'Driscoll G, Green DJ, Jones TW, Davis EA. Exercise alone reduces insulin resistance in obese children independently of changes in body composition. *J Clin Endocrinol Metab* 2007; **92**: 4230-4235 [PMID: 17698905 DOI: 10.1210/jc.2007-0779]

163 **Nassis GP**, Papantakou K, Skenderi K, Triandafillopoulou M, Kavouras SA, Yannakoulia M, Chrousos GP, Sidossis LS. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. *Metabolism* 2005; **54**: 1472-1479 [PMID: 16253636 DOI: 10.1016/j.metabol.2005.05.013]

164 **Ferguson MA**, Gutin B, Le NA, Karp W, Litaker M, Humphries M, Okuyama T, Riggs S, Owens S. Effects of exercise training and its cessation on components of the insulin resistance syndrome in obese children. *Int J Obes Relat Metab Disord* 1999; **23**: 889-895 [PMID: 10490792 DOI: 10.1038/sj.ijo.0800968]

165 **Mirabelli M**, Chiefari E, Arcidiacono B, Corigliano DM, Brunetti FS, Maggisano V, Russo D, Foti DP, Brunetti A. Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. *Nutrients* 2020; **12** [PMID: 32290535 DOI: 10.3390/nu12041066]

166 **Tavares LF**, Fonseca SC, Garcia Rosa ML, Yokoo EM. Relationship between ultra-processed foods and metabolic syndrome in adolescents from a Brazilian Family Doctor Program. *Public Health Nutr* 2012; **15**: 82-87 [PMID: 21752314 DOI: 10.1017/S1368980011001571]

167 **Scharf RJ**, DeBoer MD. Sugar-Sweetened Beverages and Children's Health. *Annu Rev Public Health* 2016; **37**: 273-293 [PMID: 26989829 DOI: 10.1146/annurev-publhealth-032315-021528]

168 **Steffen LM**, Jacobs DR Jr, Murtaugh MA, Moran A, Steinberger J, Hong CP, Sinaiko AR. Whole grain intake is associated with lower body mass and greater insulin sensitivity among adolescents. *Am J Epidemiol* 2003; **158**: 243-250 [PMID: 12882946 DOI: 10.1093/aje/kwg146]

169 **Liese AD**, Roach AK, Sparks KC, Marquart L, D'Agostino RB Jr, Mayer-Davis EJ. Whole-grain intake and insulin sensitivity: the Insulin Resistance Atherosclerosis Study. *Am J Clin Nutr* 2003; **78**: 965-971 [PMID: 14594783 DOI: 10.1093/ajcn/78.5.965]

170 **Salles BIM**, Cioffi D, Ferreira SRG. Probiotics supplementation and insulin resistance: a systematic review. *Diabetol Metab Syndr* 2020; **12**: 98 [PMID: 33292434 DOI: 10.1186/s13098-020-00603-6]

171 **Shen J**, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. *Mol Aspects Med* 2013; **34**: 39-58 [PMID: 23159341 DOI: 10.1016/j.mam.2012.11.001]

172 **Kelishadi R**, Salek S, Salek M, Hashemipour M, Movahedian M. Effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome: a triple-masked controlled trial. *J Pediatr (Rio J)* 2014; **90**: 28-34 [PMID: 24140383 DOI: 10.1016/j.jped.2013.06.006]

173 **Akhlaghi F**, Matson KL, Mohammadpour AH, Kelly M, Karimani A. Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus. *Clin Pharmacokinet* 2017; **56**: 561-571 [PMID: 27832452 DOI: 10.1007/s40262-016-0472-6]

174 **Chao AM**, Wadden TA, Berkowitz RI. The safety of pharmacologic treatment for pediatric obesity. *Expert Opin Drug Saf* 2018; **17**: 379-385 [PMID: 29411652 DOI: 10.1080/14740338.2018.1437143]

175 **Di Paolo S**. Metformin ameliorates extreme insulin resistance in a patient with anti-insulin receptor antibodies: description of insulin receptor and postreceptor effects in vivo and in vitro. *Acta Endocrinol (Copenh)* 1992; **126**: 117-123 [PMID: 1543016 DOI: 10.1530/acta.0.1260117]

176 **Rique S**, Ibáñez L, Marcos MV, Carrascosa A, Potau N. Effects of metformin on androgens and insulin concentrations in type A insulin resistance syndrome. *Diabetologia* 2000; **43**: 385-386 [PMID: 10768102 DOI: 10.1007/s001250050059]

177 **Horakova O**, Kroupova P, Bardova K, Buresova J, Janovska P, Kopecky J, Rossmeisl M. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. *Sci Rep* 2019; **9**: 6156 [PMID: 30992489 DOI: 10.1038/s41598-019-42531-0]

178 **Tagi VM**, Giannini C, Chiarelli F. Insulin Resistance in Children. *Front Endocrinol (Lausanne)* 2019; **10**: 342 [PMID: 31214120 DOI: 10.3389/fendo.2019.00342]

179 **Rehfeld JF**. The Origin and Understanding of the Incretin Concept. *Front Endocrinol (Lausanne)* 2018; **9**: 387 [PMID: 30061863 DOI: 10.3389/fendo.2018.00387]

180 **Aroor AR**, Manrique-Acevedo C, DeMarco VG. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. *Cardiovasc Diabetol* 2018; **17**: 59 [PMID: 29669555 DOI: 10.1186/s12933-018-0704-1]

181 **Zinman B**, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. *Can J Diabetes* 2016; **40**: 50-57 [PMID: 26474870 DOI: 10.1016/j.jcjd.2015.06.010]

182 **Guo C**, Huang T, Chen A, Chen X, Wang L, Shen F, Gu X. Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. *Braz J Med Biol Res* 2016; **49**: e5826 [PMID: 27878229 DOI: 10.1590/1414-431X20165826]

183 **Diz-Chaves Y**, Herrera-Pérez S, González-Matías LC, Lamas JA, Mallo F. Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress. *Nutrients* 2020; **12** [PMID: 33126672 DOI: 10.3390/nu12113304]

184 **Danne T**, Biester T, Kapitzke K, Jacobsen SH, Jacobsen LV, Petri KCC, Hale PM, Kordonouri O. Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years. *J Pediatr* 2017; **181**: 146-153.e3 [PMID: 27979579 DOI: 10.1016/j.jpeds.2016.10.076]

185 **Poulsen SB**, Fenton RA, Rieg T. Sodium-glucose cotransport. *Curr Opin Nephrol Hypertens* 2015; **24**: 463-469 [PMID: 26125647 DOI: 10.1097/MNH.0000000000000152]

186 **Baker C**, Wason S, Banks P, Sawhney S, Chang A, Danne T, Gesty-Palmer D, Kushner JA, McGuire DK, Mikell F, O'Neill M, Peters AL, Strumph P. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial. *Diabetes Obes Metab* 2019; **21**: 2440-2449 [PMID: 31264767 DOI: 10.1111/dom.13825]

187 **Kern M**, Klöting N, Mark M, Mayoux E, Klein T, Blüher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. *Metabolism* 2016; **65**: 114-123 [PMID: 26773934 DOI: 10.1016/j.metabol.2015.10.010]

188 **Mirza AZ**, Althagafi II, Shamshad H. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications. *Eur J Med Chem* 2019; **166**: 502-513 [PMID: 30739829 DOI: 10.1016/j.ejmech.2019.01.067]

189 **Botta M**, Audano M, Sahebkar A, Sirtori CR, Mitro N, Ruscica M. PPAR Agonists and Metabolic Syndrome: An Established Role? *Int J Mol Sci* 2018; **19** [PMID: 29662003 DOI: 10.3390/ijms19041197]

190 **Tenenbaum A**, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. *Cardiovasc Diabetol* 2012; **11**: 125 [PMID: 23057687 DOI: 10.1186/1475-2840-11-125]

191 **Kalra S**, Gandhi A, Kalra B, Agrawal N. Management of dyslipidemia in children. *Diabetol Metab Syndr* 2009; **1**: 26 [PMID: 19995441 DOI: 10.1186/1758-5996-1-26]

192 **Kersten S**. Peroxisome proliferator activated receptors and obesity. *Eur J Pharmacol* 2002; **440**: 223-234 [PMID: 12007538 DOI: 10.1016/s0014-2999(02)01431-0]

193 **Janani C**, Ranjitha Kumari BD. PPAR gamma gene--a review. *Diabetes Metab Syndr* 2015; **9**: 46-50 [PMID: 25450819 DOI: 10.1016/j.dsx.2014.09.015]

194 **Aljada A**, Ghanim H, Friedman J, Garg R, Mohanty P, Dandona P. Troglitazone reduces the expression of PPARgamma while stimulating that of PPARalpha in mononuclear cells in obese subjects. *J Clin Endocrinol Metab* 2001; **86**: 3130-3133 [PMID: 11443177 DOI: 10.1210/jcem.86.7.7624]

195 **Gu MX**, Liu XC, Jiang L. [Effect of peroxisome proliferator-activated receptor-gamma on proliferation of airway smooth muscle cells in mice with asthma]. *Zhongguo Dang Dai Er Ke Za Zhi* 2013; **15**: 583-587 [PMID: 23866284]

196 **Derosa G**, Cicero AF, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. *J Clin Pharm Ther* 2012; **37**: 187-195 [PMID: 21812797 DOI: 10.1111/j.1365-2710.2011.01280.x]

197 **McDuffie JR**, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. *Obes Res* 2002; **10**: 642-650 [PMID: 12105286 DOI: 10.1038/oby.2002.87]

198 **McDuffie JR**, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Frazer TE, Van Hubbard S, Yanovski JA. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. *J Pediatr Endocrinol Metab* 2004; **17**: 307-319 [PMID: 15112907 DOI: 10.1515/jpem.2004.17.3.307]

199 **Araújo JR**, Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. *Curr Neuropharmacol* 2012; **10**: 49-52 [PMID: 22942877 DOI: 10.2174/157015912799362788]

200 **Vuorio A**, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev* 2017; **7**: CD006401 [PMID: 28685504 DOI: 10.1002/14651858.CD006401.pub4]

201 **Xu Y**, Jiang W, Chen G, Zhu W, Ding W, Ge Z, Tan Y, Ma T, Cui G. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. *Adv Clin Exp Med* 2017; **26**: 333-338 [PMID: 28791854 DOI: 10.17219/acem/61609]

202 **Legrand DA**, Scheen AJ. [Aspirin for primary prevention of cardiovascular diseases in diabetic patients: focus on gender difference and insulin resistance]. *Rev Med Liege* 2006; **61**: 682-690 [PMID: 17209500]

203 **Thenappan A**, Nadler E. Bariatric Surgery in Children: Indications, Types, and Outcomes. *Curr Gastroenterol Rep* 2019; **21**: 24 [PMID: 31025124 DOI: 10.1007/s11894-019-0691-8]

204 **Schauer PR**, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. *Ann Surg* 2003; **238**: 467-84; discussion 84-5 [PMID: 14530719 DOI: 10.1097/01.sla.0000089851.41115.1b]

205 **Rao RS**, Yanagisawa R, Kini S. Insulin resistance and bariatric surgery. *Obes Rev* 2012; **13**: 316-328 [PMID: 22106981 DOI: 10.1111/j.1467-789X.2011.00955.x]

206 **van de Pas KGH**, Bonouvrie DS, Janssen L, Roebroek YGM, Zegers BSHJ, Leclercq WKG, Vreugdenhil ACE, van Dielen FMH. Bariatric Surgery in Youth: the Perspective of Dutch Pediatricians, Parents, and Adolescents. *Obes Surg* 2021; **31**: 4821-4828 [PMID: 34357532 DOI: 10.1007/s11695-021-05648-8]

207 **Wasserman H**, Inge TH. Bariatric surgery in obese adolescents: opportunities and challenges. *Pediatr Ann* 2014; **43**: e230-e236 [PMID: 25198448 DOI: 10.3928/00904481-20140825-10]

208 **Patni N**, Garg A. Congenital generalized lipodystrophies--new insights into metabolic dysfunction. *Nat Rev Endocrinol* 2015; **11**: 522-534 [PMID: 26239609 DOI: 10.1038/nrendo.2015.123]

209 **Berglund L**, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF; Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012; **97**: 2969-2989 [PMID: 22962670 DOI: 10.1210/jc.2011-3213]

210 **Simsir IY**, Yurekli BS, Polat I, Saygili F, Akinci B. Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy. *Natl Med J India* 2020; **33**: 278-280 [PMID: 34213454 DOI: 10.4103/0970-258X.317476]

211 **Backeljauw PF**, Alves C, Eidson M, Cleveland W, Underwood LE, Davenport ML. Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. *Pediatr Res* 1994; **36**: 749-754 [PMID: 7534902 DOI: 10.1203/00006450-199412000-00012]

212 **Weber DR**, Stanescu DE, Semple R, Holland C, Magge SN. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. *J Pediatr Endocrinol Metab* 2014; **27**: 1237-1241 [PMID: 25153212 DOI: 10.1515/jpem-2013-0402]

213 **Bitkin EC**, Boyraz M, Taşkın N, Akçay A, Ulucan K, Akyol MB, Akçay T. Effects of ACE inhibitors on insulin resistance and lipid profile in children with metabolic syndrome. *J Clin Res Pediatr Endocrinol* 2013; **5**: 164-169 [PMID: 24072084 DOI: 10.4274/Jcrpe.1020]

214 **Israili ZH**, Lyoussi B, Hernández-Hernández R, Velasco M. Metabolic syndrome: treatment of hypertensive patients. *Am J Ther* 2007; **14**: 386-402 [PMID: 17667215 DOI: 10.1097/01.pap.0000249936.05650.0c]

215 **Mann JP**, Valenti L, Scorletti E, Byrne CD, Nobili V. Nonalcoholic Fatty Liver Disease in Children. *Semin Liver Dis* 2018; **38**: 1-13 [PMID: 29471561 DOI: 10.1055/s-0038-1627456]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 18, 2022

**First decision:** March 11, 2022

**Article in press:** March 27, 2022

**Specialty type:** Pediatrics

**Country/Territory of origin:** Bahrain

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Herold Z, Hungary; Liao JX, China; Wang CR, Taiwan **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H

**Figure Legends**



**Figure 1 Different lines for management of insulin resistance.** DPP4: Dipeptidyl peptidase-4 inhibitors; GLP-1: Glucagon-like peptide-1; PPAR: Peroxisome proliferator-activated receptor; SNDRI: Serotonin-norepinephrine-dopamine reuptake inhibitor.

**T****able 1 Various types of insulin resistance in children**

|  |  |
| --- | --- |
| **IR type** | **Description** |
| Partial IR | The impairment of insulin receptor expression is limited to specific tissue and consequently exhibits some features of insulin resistance according to the tissue affected |
| Complete IR | The impairment of insulin receptor expression is extensively distributed all over the body tissues and organs with the full expression of the syndrome |
| IR syndrome type A | It is a rare type of hereditary insulin resistance syndrome due to the lack of response of the tissues to the insulin. Patients with this syndrome are nonobese and demonstrate severe hyperinsulinemia, hyperandrogenism, and acanthosis nigricans. The clinical features are more severe in affected females than in males, and they mostly become apparent at the age of puberty |
| IR syndrome type B | It is a rare disorder caused by autoantibodies to the insulin receptor. This disorder is most frequently reported in middle-aged black women and is invariably associated with other autoimmune diseases |
| Compensated IR | The resulting hyperinsulinemia compensates for the body's metabolic needs and prevents metabolic derangement |
| Non-compensated IR | There is a progressive failure of compensatory hyperinsulinemia to fulfill the body's metabolic needs through puberty with rising blood glucose and triglyceride levels and metabolic derangement |
| Early childhood IR | Onset before the age of ten, a metabolic syndrome diagnosis cannot be made, but further measures should be taken if one of the parents has metabolic syndrome, DM type-II, dyslipidemia, cardiovascular risk factors, hypertension, or obesity |
| Late childhood IR | Onset after ten years of age, diagnosis of metabolic syndrome can be made |
| Social IR | It is a negative attitude directed towards avoiding or rejecting insulin therapy by some social groups |

DM: Diabetes mellitus; IR: Insulin resistance.

**Table 2 Various causes of the genetic type of insulin resistance**

|  |  |  |
| --- | --- | --- |
| **Site of defect** | **Type of defect** | **Clinical features** |
| Insulin receptor: Mutations in the *INSR* gene (19p13.2) → faulty insulin receptor that cannot transmit signals properly | Type A IR syndrome mutation in the *INSR* gene (19p13.2) | Females are more affected than males. Appear during adolescence (delayed menses, 1ry amenorrhea, oligomenorrhea, hirsutism, acanthosis nigricans). Some males may have hypoglycemia & occasionally acanthosis nigricans. Later, they may develop DM |
| Leprechaunism or Donohue syndrome (extremely rare) autosomal recessive | Extreme insulin resistance with fasting hypoglycemia and postprandial hyperglycemia, low birth weight, distinctive craniofacial features (bulging eyes, protuberant and low-set ears, thick lips, and upturned nostrils), skin abnormalities (hyperkeratosis), enlargement of the breast and clitoris in females and the penis in males, growth delays, & features of other endocrinopathies |
| Rabson-Mendenhall syndrome (rare) autosomal recessive, also include Donohue syndrome | Severe insulin resistance, low birth weight, failure to thrive, lack of subcutaneous fat, muscle wasting, dental abnormalities; hirsutism, polycystic ovaries in females; enlargement of the nipples, genitalia, kidneys, heart, and other organs. Most affected individuals also have acanthosis nigricans, and distinctive facial features include prominent hypertelorism; a broad nose; and large, low-set ears |
| Polymorphism in PC-1 | It causes PC-1 overexpression to reduce autophosphorylation of the insulin receptor β-subunit, impairs insulin stimulation of insulin receptor activation & downstream signaling with short at birth, hyperinsulinemia, and high insulin resistance, high prevalence of diabetes, hypertension, and preeclampsia |
| Defects in fat cell and lipid homeostasis pathway | Congenital generalized lipodystrophy (mutations in *BSCL2* on 11q13, & *AGPAT2* gene on 9q34) | Autosomal recessive, extreme lack of body fat, and severe insulin resistance since birth |
| Kobberling's syndrome (mutation in the *PPAR-δ* gene) FPL type 1 | X-linked dominant, lethal in the hemizygous male. The autosomal dominant form of familial partial lipodystrophy was also described, characterized by the absence of subcutaneous fat, and presence of adipose tissue inside the body cavities and skeletal muscle hypertrophy. Fat loss is generally confined to the arms and legs. Fat loss is usually more prominent on the arms and legs' lower (distal) portions than proximal |
| Dunnigan's syndrome (*LMNA* gene mutation) (1q22) FPL type 2 | An X-linked dominant, lethal in hemizygous males, present with partial lipodystrophy characterized by sparing of the face. The onset of lipodystrophy usually occurs at or around puberty, with improper fat distribution (loss of fat in the limbs and gluteal region and variable regional fat accumulation on the face, neck, and axillary regions giving patients a cushingoid appearance). Females often have a more severe phenotype than males. An increased skeletal muscle volume and mass are also noted. Prominent veins (due to lipoatrophy) are noted in the limbs |
| Allelic variation in PPAR-δ, PPAR-α, polymorphism of *UCP1*, *UCP2*, *UCP3* genes & polymorphism of β-2 and β-3 adrenergic receptor | Allelic variation in PPAR-δ influences body fat mass by effects on adipocyte; polymorphisms of *PPAR-α* gene can lead to higher triglyceride and insulin levels; polymorphism of the lipoprotein lipase gene was both linked and associated with insulin resistance; polymorphism of *UCP1*, *UCP2*, *UCP3* genes are associated with marked adiposity and DM type II; and polymorphism of β-2 and β-3 adrenergic receptors associated with chronic non-communicable disorders, such as cardiovascular diseases, asthma, chronic obstructive pulmonary disease, and obesity, as well as β-agonists and antagonists response and toxicity |
| Proteases CALP10 | *CALP10* gene polymorphism | It is associated with reduced muscle mRNA levels and insulin resistance, metabolic syndrome, type II DM, and polycystic ovary syndrome |
| Other hormonal disorders | *POMC* mutations | Causes mutations in the *POMC* gene were linked with a clinical phenotype of adrenal insufficiency, red hair pigmentation, early-onset and rapidly progressive obesity, early-onset type 2 diabetes, hypothyroidism, hypogonadism, and growth hormone deficiency |
| The *MC4R* gene mutations | MC4R mutations are the most common form of monogenic obesity and have been implicated in 1% to 6% of early-onset severe obesity |
| The *MC3R* gene mutations | Inactivating mutations in the *MC3R* gene causes obesity in mice but is not clear in human |
| Leptin and leptin receptor mutations | Homozygous leptin gene mutations are associated with the early onset of severe obesity and diverse impairment of physiological functions. Recessive leptin receptor mutations are associated with similar pathology in the homozygous state |
| Ghrelin polymorphisms | Ghrelin is an orexigenic peptide that stimulates appetite and induces body weight gain and adipogenesis. Ghrelin polymorphisms may be associated with obesity and obesity-related phenotypes |
| *NPY* gene | *NPY* gene polymorphism is associated with an increased risk of metabolic syndrome and its related phenotypes, such as central obesity and hyperglycemia |
| *CART* polymorphisms | *CART* gene polymorphism is associated with a genetic predisposition to insulin resistance & obesity |
| *ER* mutations | *ER* mutations cause impaired insulin sensitivity/glucose intolerance, hyperinsulinemia, and obesity |
| Prader-Willi syndrome | 15q11.2–q12, uniparental maternal disomy | A key feature of Prader-Willi syndrome is a constant sense of hunger (hyperphagia) that usually begins at about 2 years of age with several physical, mental, and behavioral problems |
| Alström syndrome | Mutations in the *ALMS1* gene | The *ALMS1* gene provides instructions for making a protein whose function is unknown. *ALMS1* gene mutants in the hypothalamus might lead to hyperphagia followed by obesity and insulin resistance |
| Bardet-Biedl syndrome | Mutations in at least 14 different genes (often called *BBS* genes) | Vision loss is one of the significant features of Bardet-Biedl syndrome. Obesity is another characteristic feature of Bardet-Biedl syndrome. Abnormal weight gain typically begins in early childhood and continues to be an issue throughout life |
| Cohen syndrome | Mutations in the *VPS13B* gene (also called the *COH1* gene) | Cohen syndrome is an inherited disorder that affects many parts of the body and is characterized by developmental delay, intellectual disability, microcephaly, and weak muscle tone (hypotonia). Obesity develops in late childhood or adolescence |
| Biemond syndrome II |  | Biemond syndrome type II is a rare genetic neurological & developmental disorder reported in few patients with a poorly defined phenotype, including iris coloboma, short stature, obesity, hypogonadism, and postaxial polydactyly, and intellectual disability |

### DM: Diabetes mellitus; IR: Insulin resistance; PPAR: Peroxisome proliferator-activated receptor. UCP1, UCP2 and UCP3 are the uncoupling protein homologs.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**